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Abstract  
Neisseria meningitidis is a human pathogen which can cause fatal sepsis and invasive 
meningococcal disease once it reaches the blood stream and the nervous system. Bexsero™ is the 
first broadly protective multicomponent vaccine against serogroup B N. meningitidis. Among its 
components, the Neisserial Heparin Binding Antigen (NHBA) represents the less structurally and 
functionally characterized antigen of Bexsero and therefore has been the target of the current study. 
NHBA is a surface-exposed lipoprotein composed by two domains (C- and N-terminal), and while the 
structure of the C-terminal domain was solved by NMR, the structure of N-terminal region is still 
unknown and predicted to be largely unstructured. Knowledge of the NHBA full-length structure can 
provide important insights towards the understanding of its biological function, as well as on its role as 
vaccine antigen. 
In this work we combined the information derived from the profiling the B-cell repertoire in 
response to vaccination with Bexsero with structural biology, in order to shed light on NHBA structure 
and on the molecular bases of its recognition by the human immune system. By using fragments 
antigen binding (Fabs) derived from human monoclonal antibodies (mAbs), we sought to provide high-
resolution epitope mapping of the NHBA immunogenic regions, which in turn could permit a deeper 
characterization of the molecular determinants of antibody binding and protective epitopes.  
Here we present a structural characterization of the first high-resolution crystal structures of three 
free human anti-NHBA Fabs of NHBA. These structures reveal features compatible with the binding of 
NHBA regions as previously determined by other low-resolution methods. Moreover, these Fabs 
provided important tools for structural studies through co-crystallization experiments with various 
NHBA fragments and constructs. While using Fabs that bind to the NHBA N-terminal region 
complexed with full length or sub-full length antigen did not result in crystal growth, a construct 
including solely the C-terminal domain yielded crystals that allowed solving the structure of the 
complex with a C-terminal Fab binder. Structural analysis highlighted the conservation of the epitope 
and lead to the identification of the key residues involved into NHBA-Fab recognition. Additionally, the 
comparison between bound and unbound Fab revealed an interesting fitting mechanism occurring 
during antigen recognition that provides further details into the elucidation of antibody binding. 
Combined together, these results enhance our structural and biophysical understanding of NHBA, 
and provide a platform for deeper analyses aimed at the elucidation of the molecular determinants of 
its immunogenicity.  
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Sommario 
Neisseria meningitidis è un patogeno umano obbligato e un potenziale agente eziologico di sepsi 
e meningite, qualora entri in contatto con il flusso sanguigno o il sistema nervoso. Bexsero è il primo 
vaccino multicomponente in grado di fornire ampia protezione contro il sierogruppo B di N. 
meningitidis. Tra i vari componenti di Bexsero, Neisserial Heparin Binding Antigen (NHBA) 
rappresenta l’antigene meno caratterizzato sia funzionalmente che strutturalmente e, per questa 
ragione, è stato selezionato come oggetto di studio nel presente lavoro. NHBA è una lipoproteina 
esposta sulla superficie del batterio e si compone di due domini (C- e N-terminale); mentre la struttura 
del dominio C-terminale è stata risolta tramite spettroscopia NMR, il dominio N-terminale è ancora 
strutturalmente non caratterizzato e predetto, per la maggior parte della sua sequenza, come non-
strutturato. La conoscenza delle caratteristiche strutturali della proteina intera, quindi, potrebbe essere 
utile per chiarire il ruolo che NHBA svolge sia dal punto di vista biologico sia come antigene vaccinale.  
In questo lavoro di tesi, informazioni derivanti dall’analisi del repertorio delle cellule B generate in 
risposta all’immunizzazione con Bexsero sono state combinante con tecniche di biologia strutturale 
(cristallografia a raggi X), in modo da delucidare la struttura completa di NHBA e le basi molecolari del 
suo riconoscimento da parte del sistema immunitario umano. Frammenti di anticorpi leganti l'antigene 
(Fabs), derivanti da anticorpi monoclonali umani (mAbs) sono stati utilizzati per la mappatura ad alta 
risoluzione degli epitopi immunogenici di NHBA, permettendo un’accurata caratterizzazione dal punto 
di vista molecolare delle regioni dell’antigene implicate nel legame con gli anticorpi. 
Dall’analisi delle strutture cristallografiche ad alta risoluzione di tre Fabs umani diretti contro 
NHBA, è emerso che questi presentano a livello del paratopo caratteristiche che indicano la loro 
compatibilità con il legame a NHBA tramite regioni precedente mappate con tecniche a bassa 
risoluzione. Inoltre, questi Fabs si sono rivelati un importante strumento per studi strutturali attraverso 
esperimenti di co-cristallizzazione in complesso con NHBA. Purtroppo non è stato possibile ottenere 
cristalli idonei per esperimenti di diffrazione dalla co-cristallizzazione dei Fabs con l’intera NHBA o 
frammenti N-terminali di NHBA; al contrario, il dominio C-terminale dell’antigene in complesso con un 
Fab ha generato cristalli che hanno permesso di risolvere la prima struttura di un complesso tra C-
terminale di NHBA e un Fab umano. L’analisi strutturale di questo complesso ha evidenziato l’estrema 
conservazione dell’epitopo e guidato l’identificazione dei residui chiave implicati nel riconoscimento tra 
NHBA e Fab. Inoltre, il confronto tra la forma complessata e non-complessata del Fab ha rivelato un 
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interessante meccanismo di legame che avviene nella fase di riconoscimento dell’antigene e che 
fornisce ulteriori dettagli sui meccanismi che regolano i legami tra anticorpi e antigeni.  
I risultati ottenuti in questo studio hanno contribuito a migliorare la conoscenza strutturale e 
biofisica di NHBA e forniscono una base per una futura analisi strutturale più accurata, volta a 
delucidare i dettagli molecolari della risposta immunitaria a NHBA.  
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Introduction  
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Reverse Vaccinology & Structural Vaccinology 
Vaccines are one of the most successful medical interventions against infectious diseases [1], and 
vaccination is thought to prevent an estimated 2.5 million deaths each year [2]. The aim of most 
vaccinations is to confer protection against microorganisms, and their action is based on the ability to 
elicit an immune response [3]. Vaccines have been historically developed by the “isolating, 
inactivating, and injecting” approach [4]. This empirical method used as vaccines mixtures of  disease-
causing agents after their attenuation (i.e. bacteria killed by heat or chemical treatment, and that 
retained immunogenicity) [5]. Today, novel technologies allow for a “rational” approach to vaccine 
development, with advances in areas such as genome sequencing and proteomics that almost 20 
years ago provided the bases for a revolution in the field, the so-called Reverse Vaccinology (RV) [6-
9]. 
The complete genome of a pathogen provides key information on genes that encode for potential 
antigens, which can thus be selected and tested as candidates for vaccine development by use of 
bioinformatics tools and without the need, in this first phase, to grow pathogens. For example, 
bioinformatics is used to select open reading frames (ORFs) that encode putative surface-exposed or 
secreted proteins, which can potentially be recognized by antibodies. This stage of identification can 
be performed in silico by searching for specific properties like the presence of signal peptide 
sequences or motifs, and of membrane spanning regions. Sequence homology analyses allow then to 
gain additional critical information on the candidate antigens such as homology both to other known 
virulence factors or protective antigens (from other pathogens), and to human proteins (to avoid 
autoimmune issues) [10]. In addition to genome sequencing, also mass spectrometry and proteomics 
play a significant role in modern vaccine development projects [11-14]. Once the initial candidates are 
identified and selected, these will then be produced as recombinant proteins for further 
characterization, and will then be tested for their immunogenicity in animal models. This will provide 
experimental evidence of their potential use as vaccine candidates.  
The value of RV has been recently demonstrated with the discovery and development of Bexsero, 
the broadly protective vaccine against Neisseria meningitidis serogroup B [13] (Fig.1.1). In addition, 
RV has been also used to aid the identification of vaccine candidates for several other bacterial 
pathogens, and recently also for herpes simplex virus [15-19].  
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Technological advances in areas such as human immunology and structural biology are also 
providing key new tools for vaccine research and development. Modern capabilities to profile the 
antigen-specific B-cell repertoire and characterize the corresponding antibodies represent powerful 
tools for the study of the specific immune response upon immunization [20]. Using information and 
knowledge derived from the B-cell repertoire as a starting point for structural biology studies has also 
already given remarkable breakthroughs in vaccine research [21]. For example, several studies that 
use structure-based methods applied to vaccine research and development have been recently 
published on targets for different diseases like respiratory syncytial virus (RSV) [22], human 
immunodeficiency virus1 (HIV-1) [23], MenB [24] and group B streptococcus (GBS) [25]. Structural 
knowledge of protein antigens and of complexes between antigens and antibodies can provide the 
molecular or atomic bases to drive optimization and to enable design of more stable, homogeneous, 
immunogenic, and affordable vaccine antigens [26]. The combination of experimental structure-
determination methods such as nuclear magnetic resonance (NMR), X-ray crystallography, and 
electron microscopy (EM), with computational methods like epitope predictions, structure modeling 
and design, can potentially provide the tools for a new revolution in vaccine research, what is now 
known as Structural Vaccinology (SV) [10].  
 
Figure 1.1. Example of the RV approach applied to meningococcus serogroup B.  Bioinformatics is used for 
prediction of genes encoding vaccine candidate antigens that are i) exposed on the bacterial surface, ii) antigenically 
conserved, and iii) do not contain sequences that are similar to human proteins. Selected genes are expressed in E. 
coli and then the proteins are purified and used for mice immunization. The sera of the mice are tested for their 
bactericidal killing in the presence of complement. The 'best' antigens are then selected for vaccine development 3.  
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One of the common applications of SV in vaccine research is the structural characterization of the 
immune response through epitope mapping, which provides the molecular details of antigen 
recognition by the host immune system. This translates into a three-dimensional map of the residues 
and atoms of a certain antigen that constitute its immunogenic regions [27-29], also known as 
epitopes, with obvious important implications for design strategies. The structure of vaccine antigens 
can also be used for structure-based optimization aimed at improving stability [30] and homogeneity of 
a candidate, stabilizing its fold [31], or reducing its degradation and aggregation tendencies. Structure 
is also a key starting point in order to engineer molecules in order to overcome sequence variability 
and the impact that this has on immune recognition. For example, SV can guide the design of chimeric 
antigens that display epitopes derived from multiple variants, resulting in the elicitation of a wider 
immune response, as previously reported for the meningococcal factor H binding protein (fHbp) [24]. 
In this study, starting from the structure of fHbp that was previously elucidated by NMR spectroscopy 
and X-ray crystallography, epitope mapping was performed using bactericidal antibodies against three 
sequence variants. Information on the variant specific epitopes recognized by these antibodies was 
then used for the design of an engineered fHbp molecule containing several cross-protective B cell 
epitopes on one single common scaffold. The choice of the scaffold in this case was the fHbp 
molecule itself, being its overall structure well conserved among the three variants, and being the 
variable regions only localized on its surface. Importantly, the newly generated chimeric antigen 
showed the ability to elicit broadly protective antibodies that could target different fHbp variants and 
sub-variants commonly circulating [24]. 
 
            Figure 1.2. The structural vaccinology approach. Adapted from [26]. 
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Neisseria meningitidis and Meningococcal disease 
Neisseria meningitidis is a gram negative bacterium of the bacterial family Neissiriaceae, which 
possess a spherical or kidney-like shape. It is a non-motile and non-sporulating encapsulated and 
piliated aerobic diplococcus, and as other gram negatives possesses an outer membrane that is 
composed of lipids, outer membrane proteins (OMPs), lipo-oligosaccharides (LOS), a peptidoglycan 
layer, and a lipopolysaccharide (LPS). The LPS plays a role in serum resistance and thus in the 
pathogenesis [32], while the polysaccharide capsule, which is present in almost all N. meningitidis 
strains, is responsible for invasive disease, being crucial for the survival in the blood, the resistance to 
antibody/complement mediated killing, and inhibition of phagocytosis. According to the different 
structures and composition of the capsule, 12 different meningococcal serogroups have been defined 
[33, 34] of which five, A, B, C, W135 and Y, are responsible of more than 95% of the disease [35]. 
Further classification into serosubtype, serotype and immunotype is based on class 1 outer membrane 
proteins (PorA), class 2 or 3 (PorB) outer membrane proteins and lipopolysaccharide structure, 
respectively [36, 37].  
N. meningitidis is a commensal that colonizes the mucosal epithelium of the nasopharynx of 
approximately the 10% of the population, with humans being its unique reservoir [38]. The rate of 
asymptomatic carriage increases with conditions such as household crowding, and at different ages 
with a peak in adolescents. Under particular circumstances, and in susceptible individuals, 
meningococcus can become pathogenic and can cause meningitis and sepsis [39]. Although the 
events that lead to bacterial invasion are not well understood, lack of a protective immune response 
and environmental factors that damage the nasopharyngeal mucosa, are thought to increase the 
incidence of invasive meningococcal disease. For unknown factors that depend both on the host and 
on the pathogen, meningococcus can invade the pharyngeal mucosal epithelium and disseminate into 
the blood-stream causing septicemia [40], or can cross the blood-brain barrier and enter the 
cerebrospinal fluid, causing meningitis [41] (Fig. 1.3). 
 From exposure to the onset of meningococal disease, the average incubation time is between two 
and ten days [37], with symptoms of stiff neck, high fever, sensitivity to light, confusion, headache, and 
vomiting. Although the disease is rare, it causes death in 10-15% of the cases, and typically within 24 
to 48 hours of symptoms onset [37, 42].  Among survivors, 10% to 20% present permanent disability 
such as hearing loss, limb loss, cognitive dysfunction, visual impairment, educational difficulties, 
developmental delays, motor nerve deficits, seizure disorders, and behavioral problems [36].  
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Meningococcal vaccines 
The emergence of N. meningitidis strains with epidemic potential, as well as the change in 
serogroup circulation is still unpredictable [43]. Moreover, the rapid progression and the difficulties to 
diagnose meningococcal disease [36] make preventive vaccination the most effective option. 
A number of glycoconjugate vaccines against meningococcus are currently available as 
monovalent (against serogroup A or C, i.e. MenAfriVac, Menjugate or NeisVac-C) or as tetravalent 
formulations (against serogroups A, C, W-135 and Y, i.e. Menactra, Menveo) [44]. However, for a long 
time the most critical target for vaccination remained meningococcus B, which is responsible for the 
32% of all cases in the United States and for 45–80 % in Europe [45]. Differently than for other 
serogroup-targeting vaccines (see above), a polysaccharide-based vaccine approach could not be 
used for group B meningococcus because its capsular polysaccharide contains neuraminic acid, a 
mimic of the sialic acid found in human neural tissue. Thus, in addition to being a poor immunogen in 
humans, the MenB capsular polysaccharide could be recognized as a self-antigen with potentially 
devastating consequences of auto-immune reactions [46, 47]. Consequently, efforts for the 
identification of candidates to develop a vaccine against MenB have been focused on non-capsular 
antigens and on proteins.  
Bexsero (4CMenB) is the first broadly protective recombinant multi-component vaccine against 
MenB that, as mentioned above, has been discovered and developed by Reverse vaccinology [48]. 
Originally, approximately 600 open reading frames were selected from the genome of N. meningitidis 
 
Figure 1.3. Stages in the pathogenesis of Neisseria meningitidis. The image summarizes the steps during 
meningococcal colonization and infection. Adapted from 40 
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strain MC58 that were likely to encode potential surface exposed proteins [49]. The sequences of 
these initial candidates were analyzed for their conservation among a wide range of MenB strains, and 
were later expressed as recombinant proteins in E. coli in order to elucidate their biochemical 
properties and especially to test their ability to induce bactericidal killing in mice. This work revealed 
more than 90 novel surface-located proteins, of which 28 were able to induce bactericidal antibodies. 
The most promising candidates were then selected for further studies leading to the final identification 
of the three protein components that make Bexsero [6, 50], in combination with outer membrane 
vesicles (OMVs) from a New-Zealand epidemic strain (NZ98/254). The three protein antigens of 
Bexsero are: factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and 
Neisserial adhesin A (NadA) [48, 49]. fHbp (sub-variant 1.1) and NHBA (peptide 2), are present as 
fusion proteins with two minor genome-derived Neisseria antigens (GNA), GNA2091 and GNA1030, 
respectively [13], which were included in the final vaccine formulation to further enhance 
immunogenicity of the main antigens and to facilitate large-scale manufacturing (Fig. 1.4). 
  
Clinical trials have demonstrated safety and immunogenicity of Bexsero, which is able to induce a 
protective immune response in infants, children, adolescents, and adults, against the majority of MenB 
strains [51, 52]. Bexsero has been licensed in Europe in 2013 and in the U.S. in 2015. 
A second recombinant protein-based vaccine against serogroup B, known as Trumenba, is now 
also available, and it has been discovered and developed by Pfizer. Trumenba has been licensed in 
the U.S. in 2014 for a target population of adolescents and young adults, and differently than Bexsero 
it is composed by equal amounts of two variants of lipidated fHbp (subfamily A05/var3.45 and 
subfamily B01/var1.55) [53]. During preclinical evaluation, Trumenba has been shown to have good 
breadth of coverage [54]. However, because it contains purified lipoproteins known as TLR-2 agonists, 
Trumenba is not suitable for use in infants [55]. 
           
Figure 1.4. Schematic representation of 4CMenB. 4CMenB composition: the three main recombinant antigens 
fHbp, NadA, and NHBA and the fusion proteins GNA1030 and GNA2091 (left) combined with OMV from MenB 
strain NZ 98/254 (right).  
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NHBA vaccine antigen  
NHBA (Neisserial Heparin Binding Antigen, or GNA2132), is a surface-exposed lipoprotein able to 
induce antigen-specific bactericidal antibodies in animals and humans immunized with 4CMenB [50, 
56, 57]. Moreover, NHBA is a protein specific to Neisseria species and its gene is ubiquitous in all 
Neisserial group B strains tested so far [58-61]. The NHBA-encoding gene is present also in N. 
gonorrhoeae and the commensal species N. lactamica, N. polysaccharea, and N. flavescens and, with 
the exception of N. gonorrhoeae, it is highly conserved [61]. Gene sequence analysis from genetically 
diverse group B strains revealed the existence of more than 600 peptides that possess some 
association with clonal complexes and sequence types [61, 62]. Examination of these gene 
sequences revealed also the presence of variable segments of NHBA at the level of the primary amino 
acid sequence, with the highest sequence diversity clustered in the N-terminal region of the protein 
(Fig. 1.5). In particular, sequence variability has been associated to an insertion of 60 amino acids (IB-
insertion), present only in some strains and that allows a classification of NHBA peptides in so-called 
long and short variants. The long NHBA peptide 2 (p2) variant is the one included in Bexsero, being 
this the most frequently expressed peptide found through molecular epidemiological studies in Europe 
[63].
    The amino acidic protein sequence of NHBA allows to distinguish two independently folded 
domains (N- and C-terminus) separated by a central poly-Arginine motif. The structure of the C-
terminal region (residues 246 to 427) of NHBA peptide 20 (p20) was first determined by NMR 
spectroscopy [64], revealing a single 8-stranded anti-parallel β-barrel and two β-strands in a hairpin 
conformation (Fig. 1.6A). The two β-strands are not well defined in the NMR structure, likely due to 
 
Figure 1.5. NHBA variability and modular structural organization. NHBA protein sequence reflects a modular 
structural organization, where it is possible to distinguish the N- (yellow) and C-terminal (purple) domains. The 
grey box represents the IB-insertion. Arg-rich motif (blue) is flanked by the NalP cleavage site and by the human 
lactoferrin cleavage site. The upper line illustrates the extent of the structural information currently available. The 
lower graph shows the percentage of amino acid conservation between the different peptides along the protein 
sequence. 
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the experimental conditions under which the sample was analyzed. This fold resembles that of 
members of the lipocalin superfamily, which are typically involved in the transport of small hydrophobic 
compounds such as retinol in the plasma [65], and also shows clear structural similarity with 
transferrin binding protein B (TbpB) [66] and with the C-terminal domain of fHbp (Fig. 1.6B).  
 
The Arg-rich region appears to be extremely conserved among different NHBA peptides, underlying 
its importance in bacterial pathophysiology as also confirmed by experiments that showed how this 
region allows NHBA to bind heparin in vitro. Importantly, heparin binding is also associated to 
increased survival of bacteria in human serum [56]. A complex between NHBA and heparin on the 
meningococcal cell surface could recruit complement inhibitors, which in turn could prevent 
complement activation. Also, binding of heparin by NHBA in vitro could potentially translate in vivo to 
binding of glysoaminoglycans (such as heparan sulfate) that are present in mucosal secretions. In 
fact, several other bacterial adhesins have been reported to bind heparin and heparin sulfate [13]. 
Moreover, NHBA has been shown to be susceptible to cleavage mediated by two proteases, the 
meningococcal NalP and the human lactoferrin, that cleave NHBA upstream and downstream of the 
Arg-rich region respectively releasing two fragments into the extracellular milieu [56, 67]. 
Overall, NHBA appears to contribute to meningococcus interaction with the host cells and likely to 
be involved in biofilm formation. However, NHBA specific biological function remains unknown.  
 
Figure 1.6. NHBA C-terminal structure. (A) Cartoon representation of NHBA C-terminal ensemble of structures 
determined by NMR spectroscopy (PDB ID 2LFU). (B) Cartoon representations of proteins with significant 
structural similarity to NHBA determined by X-ray crystallography. From left to right: fHbp (PDB 3KVD), the N- 
and C-terminal repeats of TbpB (PDB 3HOL) and NspA (PDB 1P4T). 
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Antibodies: tools for studying the immune system  
The interaction between antibodies (Ab) and antigens (Ag) represent a key event for the clearance 
of microbes and foreign molecules by the immune system. Antibodies, which are generated by B-
lymphocytes and activate the humoral immune response, mainly direct binding to antigens by coating 
the surface of the invader to prevent the pathogen from entering or damaging healthy body cells. 
Antibodies also stimulate other parts of the immune system, like the complement cascade, to destroy 
pathogens, and they can mark microbes by opsonization so that they can later be recognized and 
neutralized by effector immune cells [68, 69].  
Antibodies are roughly Y-shaped glycoproteins that belong to the immunoglobulin (Ig) superfamily 
[70], and consist of a pair of β-sheets each formed of antiparallel β strands linked by a single disulfide 
bond. Antibodies are generally made of four separate polypeptide chains, two light (L; MW ∼25 kDa) 
and two heavy (H; MW ∼55 kDa). H and L chains of antibodies combine to form one Fc (Fragment 
crystallizable) domain and two Fab (Fragment antigen binding) modules. The Fc and the Fab are 
linked by a flexible “hinge” region, and can be separated by proteolytic cleavage. Furthermore, each 
Fab fragment is subdivided in two distinct structural domains named variable (VL,VH) and constant 
(CL,CH1), with the amino acid residues linking VL to CL and VH to CH1 called switch residues [68, 71] 
(Fig. 1.7). 
  
 
Figure 1.7. Antibody structure. (A) Crystal structure of the anti-canine lymphoma monoclonal antibody (PDB 
1IGT) (B) Schematic representation of an IgG molecule divided in heavy (blue) and light (red) chains. Disulfides 
bonds are highlighted in yellow. Adapted from 68 
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The Fab variable domains are responsible for antigen specificity, as they bind to the antigen 
through six hypervariable loops (L1, L2, L3, H1, H2, H3) that are commonly known as 
complementarity determining regions (CDRs) [72, 73]. Although also non-CDRs residues have been 
found to be involved in Ag recognition, these play a more modest role compared to the CDRs [74]. 
Loops forming the CDRs extend from the conserved structural framework of the Fabs and are highly 
variable in size and sequence. This allows antibodies to recognize an almost unlimited number of 
antigens [75]. Given their biological relevance, efforts in developing a rationale for CDRs identification 
and classification have been pursued [76-78]. These early studies were based on a limited number of 
structures, while the recent explosion of Fabs structures deposited in the Protein Data Bank (PDB) 
enabled a more exhaustive description of the CDRs [79]. 
The ensemble of antibody residues that in addition to the CDRs are required for Ag recognition, 
are often called “paratope”. Instead, molecular structures within any given antigen that contact the 
antibody are referred to as antibody or B-cell epitopes [80]. Knowing the structure of epitopes and of 
the epitope-paratope interfaces provides highly valuable information for the understanding not only of 
host-immune response, but also for the design of antigens with desired biochemical and 
immunological properties [81, 82]. Such knowledge can be mainly achieved by epitope mapping, 
which can be performed by several structural and non-structural methods [80, 83]. Experimental 
techniques of epitope mapping [84] include i) ELISA-based approaches, ii) Pep-Scan or Protein 
microarrays (elucidating linear peptides from the antigen protein sequence) [85-88]), iii) protein 
mutagenesis or phage display, iv) mass-spectrometry methods such as hydrogen-deuterium 
exchange coupled to mass-spectrometry (HDX-MS), and v) the more informative and high-resolution 
of all, Cryo-EM and X-ray crystallography, which can reveal the full picture of the often intricate three-
dimensional arrangement of atoms and amino acids that make the epitope-paratope interface.  
Importantly, in addition to their use to elucidate immunologically-relevant function and structures, 
antibody fragments (Fabs) can be used as chaperones to aid crystallization of their cognate antigens, 
specifically when the latter are particularly difficult to crystallize, as in the presence of protein 
containing flexible or unstructured regions or multiple domains [89]. The extreme stability of Fabs and 
their specificity generally stabilize antigen conformations or regions that otherwise might negatively 
impact the ability to form the crystal contacts necessary to obtain the ordered packing that 
distinguishes protein crystals. 
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Aims 
Despite its relevance for the generation of protective immunity as a component of the MenB 
vaccine Bexsero, the molecular details of NHBA biological function and of its recognition by the 
immune system remain yet not fully understood. A recent effort to profile the B-cell repertoire in 
response to vaccination with the Bexsero antigens enabled the isolation and characterization of 
human monoclonal antibodies (hu-mAbs) against these antigens (fHbp, NHBA, and NadA) [90, 91]. 
Specifically for this study, a set of four anti-NHBA hu-mAbs were isolated and later selected for further 
characterization including structural biology studies. Three of the initial four anti-NHBA hu-mAbs are 
the subject of the research work described in this thesis. 
The specific aims of the current work were to exploit the availability of anti-NHBA hu-mAbs in order 
to: i) elucidate the structure of the N-terminal domain of NHBA, whose 3D structure remains elusive; 
and ii) elucidate the structural bases of the NHBA recognition by the immune system. Firstly, 
fragments antigen binding (Fabs) derived from the available hu-mAbs where used as tools to increase 
the probabilities of obtaining crystals of NHBA, which alone resulted recalcitrant to crystallization. 
Secondly, the Fabs were utilized in complex with NHBA for epitope mapping studies, to provide a 
high-resolution picture of those NHBA regions involved in the recognition by the human immune 
system.  
Molecular biology, biochemical and biophysical methods, as well as X-ray crystallography, were 
the main techniques utilized in the work described in this thesis. The crystal structures of three 
unbound Fabs, called 12E1, 10C3, and 5H2, derived from the anti-NHBA hu-mAbs isolated in the 
study mentioned above, were solved at high-resolution. Moreover, the high-resolution crystal structure 
of a complex between Fab 5H2 and a C-terminal NHBA fragment (NHBA-C3) was also solved. To fully 
characterize the Fabs and the complex above, as well as NHBA alone, thermo-stability and binding 
studies were also performed.  
These results allowed to perform an in-depth analysis of the biochemical and structural properties 
of the first human antibodies against a Bexsero antigen, and to our knowledge represent the first high-
resolution structural characterization of a representative set of antibodies from the repertoire 
generated by immunization using an antigen that is already part of a commercially available vaccine. 
As such, this study provides insights that in addition to complement the full characterization of 
Bexsero, can also enable further and more advanced studies of protein design and engineering to 
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expand our understanding of how vaccines work at the atomic level, with potential implications also for 
other future vaccine development programs. 
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Materials & Methods 
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Bacterial strains 
The serogroup B N. meningitidis strains used in this study include the wild type MC58 (peptide 3), 
NZ98/254 (peptide 2), and 2996 (peptide 20). The NHBA gene fragments from N. meningitidis strains 
inserted into the pET-21b(+) vector (Novagen) were used for protein expression. Region 312-427 
(hereafter indicated as NHBA-C3) of the GNA2132 sequence form strain 2996 was cloned in a 
pET21b(+) vector (Novagen), while region 114-332 (hereafter indicated as NHBA-114-332) from strain 
NZ98/254 was cloned into a pET24b(+) vector (Novagen). All NHBA expression constructs were 
cloned without the signal peptide and a C-terminal 6-His tag was inserted for purification purposes. 
The residues numbering used here refers to the full-length NHBA peptide 20 (p20), peptide 2(p2), and 
peptide 3 (p3), with corresponding UniProt accession numbers Q9JPP1, Q9JPH1 and Q9JQW0.  
 
Figure 2.1. Domain organization and constructs of NHBA. Each expression construct had a C-terminal 6-His 
tag to enable affinity purification. The predicted domain organization and domain boundaries are shown 
schematically as boxes. 
NHBA-C3 mutants generation 
Site-directed mutagenesis on NHBA-C3 (p20) DNA sequence was performed to produce the set of 
mutants listed below. Mutants were constructed using the polymerase incomplete primer extension 
cloning method (PIPE) method. The mutagenesis reactions were transformed into chemically 
competent E. coli Mach1™-T1R (Thermo Scientific). After sequencing, each plasmid was used to 
chemically transform E. coli BL21 (DE3) T1R cells (NEB) for protein production.  
NHBA-C3 mutant Plasmid characteristics 
NHBA-C3_Arg339Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Arg339Ala mutation, AmpR 
NHBA-C3_Arg339Gly pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Arg339Gly mutation, AmpR 
NHBA-C3_Lys367Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Lys367Ala mutation, AmpR 
NHBA-C3_Arg339Ala-Lys367Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Arg339Ala-Lys367Ala mutation,  
NHBA-C3_Arg339Gly-Lys367Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Arg339Gly-Lys367Ala mutation, AmpR  
NHBA-C3_Thr365Ala-Asp360Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Thr365Ala-Asp360Ala mutation, AmpR  
NHBA-C3_Glu322Ala-Glu425Ala pET21b(+) derivative for expression of recombinant NHBAp20 312-427, containing an Glu322Ala-Glu425Ala mutation,  
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Bioinformatics analyses  
Various NHBA peptide sequences (p2, p3, p5, p1, p29, p18, p17, p10, p21) were submitted to 
several servers that perform secondary structure predictions, in each case using the standard 
parameters: Phyre2 [92, 93], SABLE [94], PSIPRED [95], and JPred4 [96]. Predictions of protein 
dynamics and disordered sequence regions were performed with DynaMine [97], IUPred [98] and 
MeDor [99]. 
NHBA production and purification  
Protein expression was performed in E. coli BL21D3 (T1r) cells (Invitrogen) [100], by using the 
EnPresso growth systems (BioSilta, Cambridge-shire, United Kingdom) supplemented with 100 mg/ml 
ampicillin. Bacteria were grown at 30°C for 12 h, and recombinant protein expression was induced by 
the addition of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 25°C for 24 h. Bacteria 
expressing NHBA-114-332 were grown in DIFCO 3X medium (45g/L Yeast Extract, 4g/L KH2PO4, 
16g/L K2HPO4, 15g/L glycerol) supplemented with 100mg/ml Kanamycin, 30 g/L glycerol and 0.25 g/L 
MgSO4, and the cells were then induced with 0.25 mM IPTG for 24 hours at 27 °C. Cells were 
harvested by centrifugation (6400g, 30 min, 4°C), re-suspended in 50 mM NaH2PO4, 300 mM NaCl, 
20 mM imidazole, pH 7.5, and were lysed by sonication (Qsonica Q700). Cell lysates were clarified by 
centrifugation at 2800g for 30 min, and the supernatant was filtered using a 0.22 µm membrane 
(Corning filter system) prior to protein purification. NHBA proteins were purified at room temperature 
(RT, 18–26 °C) using an AKTA purifier 10 system (GE Healthcare) by Ni-affinity chromatography (5 mL 
HisTrap HP or  HiTrap TALON crude, GE Healthcare) followed by size-exclusion chromatography on a 
Superdex 200 16/60 column equilibrated in 20 mM Tris–HCl, 150 mM NaCl, pH 8.0. A second 
purification step, consisting of an affinity purification based on the HiTrap Heparin HP (GE 
Healthcare), was included for the purification of NHBA-114-332 before the final size exclusion 
chromography (SEC) step common to all other proteins described here. The apparent molecular 
weight of the protein samples was calculated based on a calibration of the SEC column previously 
performed using a Standard Molecular Weight markers kit (Gel Filtration Standard, Biorad). The 
quality of the final NHBA samples was checked using 4–12% SDS–PAGE gradient gels in MES buffer. 
Fabs generation and purification 
Gene fragments corresponding to the variable heavy and light chains of the α-NHBA human Fabs 
12E1, 10C3, and 5H2 were codon optimized for mammalian expression and synthesized by Geneart 
(Life Technologies) with Eco31I site flanking gene extremities. After re-suspension in 50 µl nuclease-
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free water, the synthetic DNA strings were digested with the Eco31I restriction enzyme. Digested and 
purified DNA products were ligated into human pRS5a Igγ1, Igκ (for Fabs 5H2 and 12E1) or Igλ (for 
10C3) expression vectors containing a human Ig gene signal peptide sequence and the Eco31I 
cloning site upstream of the human IgG1 and Igκ/λ constant regions. Fabs were cloned in E. coli DH5α 
cells, using a standard ligation protocol. In the pRS5a antibody expression vectors, the transcription is 
under the CMV promotor and clones can be selected based on resistance to ampicillin. The Fabs 
were expressed with cleavable C-terminal Strep-tag II on the heavy chain 
(WSHPQFEKGGSGGGSGGGSWSHPQFEK). 
Fabs expression was achieved by transient transfection using Expi293 (Lifetechnologies) cells in 
suspension, according to the manufacturer’s protocol. Equal amounts (15 µg each/30 ml of 
transfection volume) of vector DNA codifying FabH and FabL chains were used to transfect Expi293 
cells. The cells were incubated at 37°C with a humidified atmosphere of 8% CO2 in air on an orbital 
shaker rotating at 125 rpm. Cell culture supernatant was harvested after 36 and 72h post transfection, 
clarified with centrifugation for 30min at 4000 rpm and concentrated. 
Purification of fragments antigen binding 
Human Fabs 5H2, 12E1, and 10C3 were all purified following three chromatographic steps, which 
include: i) initial affinity purification, ii) tag cleavage coupled with reverse affinity chromatography and 
iii) size exclusion chromatography. The first Strep-affinity chromatography step was performed using a 
Strep Trap HP column (GE Healthcare) in 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.5, 
exploiting the highly selective double Strep tag at the C terminus of the Fab heavy chain. The elution 
of the Fabs was achieved by adding 2.5 mM D-desthiobiotin (IBA) in running buffer. Since the 28-
amino-acid C-terminal peptide extension containing the double Strap-tag was thought to potentially 
interfere with crystallization, the sequence tags were removed by proteolytic cleavage at a preceding 
recognition sequence (ENLYFQG) using a recombinant tobacco etch virus (TEV) protease, prepared 
and purified in-house as described previously [101], at a ratio w/w Fab:TEV 50:1. The cleaved Fabs 
were separated by the free tags by performing a reverse affinity Strep-tag chromatography and 
collecting the flow-through. Fabs were further purified employing preparative size exclusion 
chromatography Superdex 200 26/600 (GE Healthcare) in buffer 20 mM Tris-HCl, 150 mM NaCl, pH 
8. The homogeneity and the purity of the Fab proteins were confirmed by SDS-PAGE 4-12% Bis-Tris 
gel (Life Technologies) using MES 1X as buffer in both reducing and non-reducing conditions and 
performing a semi-analytical size exclusion chromatography on a Superdex 3.2/300 column. The final 
concentrations of the Fabs were calculated by measuring the absorbance at 280nm. 
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Differential Scanning Calorimetry 
The thermal stability of the NHBA proteins was assessed by differential scanning calorimetry (DSC) 
using a MicroCal VP-Capillary DSC instrument (GE Healthcare). NHBA samples were prepared at a 
protein concentration of 0.4 mg/mL in PBS buffer. The DSC temperature scan ranged from 20°C to 
110°C, with a thermal ramping rate of 200°C per hour and a 4 second filter period. Data were 
analyzed by subtraction of the reference data for a sample containing buffer only, using the Origin 7 
software. All experiments were performed in duplicate, and mean values of the melting temperature 
(Tm) were determined. 
Surface Plasmon Resonance 
Surface plasmon resonance (SPR) was used to measure the binding affinity of full-length NHBA 
variants p2, p3 and p20, and of fragments NHBA-114-332 to the Fabs 12E1, 10C3 and 5H2. 
Moreover, SPR was used to assess the recognition of a set of NHBA-C3 mutants by Fab 5H2. All SPR 
experiments were performed using a Biacore T200 instrument equilibrated at 25 °C (GE Healthcare) 
and analysed through the Biacore T200 evaluation software (GE Healthcare).  
Single-cycle kinetics (SCK) experiments were performed using a commercially available Human 
Fab Capture Kit (GE Healthcare) used to immobilize a mixture of monoclonal antibodies recognizing κ 
and λ subtypes of Fab fragment light chains by amine coupling on a carboxymethylated dextran 
sensor chip (CM5; GE Healthcare). A density level yielding ∼5000-6000 response units (RU) was 
achieved. The immobilized anti-human Fab monoclonal antibodies were then used to capture ∼800-
1100 RU human Fab. Experimental SPR running buffer contained 10 mM Hepes, 150 mM NaCl, 3mM 
EDTA, 0.05% (v/v) P20 surfactant, pH 7.4 (HBS-EP). KD and kinetic parameters were calculated by 
performing a titration series of five consecutive injections of purified protein antigen diluted in HBS-EP 
at increasing concentration (flow rate of 30 µL/min) followed by a single final surface regeneration step 
with buffer containing 10 mM glycine pH 2.1 (180 s; 10 µL/min). All sensorgrams were corrected for 
nonspecific binding with readings from a protein-free reference flow cell. Data were analyzed using the 
standard SCK method [102] implemented by the Biacore T200 evaluation software (GE Healthcare). 
Each sensorgram was fitted with the 1:1 Langmuir binding model, including a term to account for 
potential mass transfer, to obtain the individual kon and koff kinetic constants. The individual values 
were then combined to derive the single averaged KD values reported.  
To assess the binding of the NHBA-C3 mutants to Fab 5H2 captured onto the sensor chip 
described above, single equimolar injections of purified NHBA-C3 mutants at a concentration of 50 nM 
28 
 
 
were performed with a flow rate of 10 µL/min. An anti-human Fab antibody–coated surface without 
captured Fab 5H2 was used as the reference channel. A blank injection of buffer only was subtracted 
from each curve, and reference sensorgrams were subtracted from experimental sensorgrams to yield 
curves representing specific binding. The data shown are representative of at least three independent 
experiments.  
Size-exclusion high-performance liquid chromatography (SE-HPLC) 
coupled with Multi-angle laser light scattering (MALLS) 
SE-HPLC was performed at room temperature (18-26°C) on an analytical size exclusion TSK 
Super SW3000 column by loading 20 µl of each sample at a concentration of ~ 40µM. Samples were 
eluted isocratically in 0.1 M NaH2PO4, 0.4 M (NH4)2SO4 buffer, at pH 7.5. Coupling SE-HPLC with 
Multi-angle laser light scattering (SE-HPLC/MALLS) NHBA p2 and NHBA-114-332 were analyzed for 
absolute molecular size in solution. Data analyses were carried out using the Astra V software (Wyatt) 
to determine the weight-average molecular mass (MW) in Daltons and the polydispersity index 
(MW/Mn) for each oligomer present in solution. Normalization of the MALLS detectors was performed 
in each analytical session by use of bovine serum albumin. 
Fab:NHBA complexes formation 
Complexes between Fabs 10C3, Fab 12E1 or 5H2 with purified NHBA proteins p2, NHBA-114-332, 
and NHBA-C3, were freshly prepared by overnight co-incubation at 4°C followed by preparative size 
exclusion chromatography in 20 mM Tris-HCl, 150 mM NaCl, pH 8.0, on a Superdex 200 16/60 (GE 
Healthcare) column. Eluted fractions were run on an SDS-PAGE 4-12% Bis-Tris gel (Life 
Technologies) in both reducing and non-reducing conditions in order to assess protein content. 
Fractions containing both complex components were pooled and protein concentration was 
determined using the Bradford method (Protein Assay, Bio-Rad), using BSA as standard reference.  
Crystallization & X-ray data collection 
Highly-purified samples of the different Fabs 10C3, 12E1, 5H2, NHBA p2, NHBA_114-332 and 
Fab:NHBA complexes were concentrated using centrifugal concentration devices with 10 kDa 
molecular weight cut-off membrane (Amicon Ultra-15 Centrifugal Filter Unit, Millipore). Concentrated 
samples were used for crystallization trials that were performed in 96-well low-profile Intelli-Plates (Art 
Robbins) using a nanodroplet sitting-drop vapour-diffusion format. Equal volumes (200 nL) of protein 
samples and crystallization buffers were mixed using a Crystal Gryphon liquid dispenser (Art Robbins 
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Instruments). Experiments were performed at 20°C and crystallization trays were imaged with the 
automatic imaging system RockImager-182 (Formulatrix). Crystallization trials were set up using 
different commercial sparse-matrix crystallization screens (Hampton Research and Molecular 
Dimension).  
Fabs crystallizations 
Crystals of Fab 12E1 (Fig. 1.2A-B) were obtained as multiple and stacked plates from a sample at 
a concentration of 19 mg/mL and using a condition containing 0.2 M potassium sodium tartrate, 0.1 M 
sodium citrate pH 5.6, 2 M ammonium sulfate. Single crystals were isolated from the clustered plates 
and were flash-frozen using 10% w/v of ethylene glycol as cryo-protectant prior to X-ray diffraction 
experiments.  X-ray data collections were performed on beamline ID-23-1 of the European 
Synchrotron Radiation Facility (ESRF) in Grenoble, France. 
Crystals of Fab 10C3 (Fig. 1.2C-D) were obtained from a large number of different conditions 
(Table 5) and using a sample at a concentration of 17 mg/mL. Crystals were cryo-protected adding 
20% w/v glycerol or 20% w/v ethylene glycol and then flash-frozen in liquid nitrogen. Diffraction data 
were collected on beamline ID-29 at ESRF. 
Crystals of Fab 5H2 (Fig. 1.2E-F) were obtained from a sample at a concentration of 9 mg/mL in a 
condition containing 0.2 M ammonium sulfate, 0.1 M sodium-cacodylate pH 6.5, 30% w/v PEG 8K. In 
this case, the cryo-protectant used to freeze these crystals was made of crystallization mother liquor 
supplemented with 15% w/v glycerol. Data collection experiments were performed on beamline ID-29 
of the ESRF.  
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Fab:NHBA complexes: crystallization and soaking experiments 
Co-crystallization trials of Fab 10C3 with either full-length NHBA or NHBA fragments did not yield 
crystals suitable for diffraction experiments. Thus, for the complex 10C3:NHBA p2 in-situ proteolysis 
[103, 104]  was attempted: the purified complex was concentrated at 30 mg/mL and α-chymotrypsin 
(JENA Bioscience) was added to the sample at a ratio protein:protease equivalent to 10000:1 w/w. 
The mixture was immediately used for setting up crystallization trials. Crystals appeared after ~60 
days of incubation in three conditions (Table 5) and were analyzed for X-ray diffraction at the 
automated beamline ID30A-1 (MASSIF-1) at ESRF. 
As an alternative strategy to obtain an Ab-Ag or Ab-epitope complex, unbound 10C3 crystals, 
obtained under different conditions (Table 5, group 3), were used for soaking experiments with a 
peptide made of a sequence corresponding to residues 247-271 of NHBA p2 protein (247-
EKLSDADKISNYKKDGKNDGKNDKF-271). The peptide was synthetized by JPT Peptide Technologies 
with an acetylated N terminus and an amidated C terminus, and after resuspension in the mother 
liquor of the crystal target, this was soaked on top of unbound 10C3 crystals, using a 10-fold molar 
excess of peptide. Incubation times varied from 1, 5, 15, 30, 60, to 90 minutes. Soaked crystals that 
 
 
Figure 2.2. Examples of anti-NHBA Fabs crystals. Crystals of Fab 12E1 grown in (A) and (B): 0.2 M 
potassium sodium tartrate, 0.1 M sodium citrate pH 5.6, 2 M ammonium sulfate. Crystals of Fab 10C3 grown in 
(C) 0.2M lithium sulfate, 0.1M Bis Tris, 25% w/v PEG 3350 and (D) 0.2M sodium chloride, 0.1M Bis Tris, 25 % 
w/v, PEG 3350. Crystals of Fab 5H2 grown in (E) 0.2M ammonium sulfate, 0.1M sodium-cacodylate pH 6.5, 30% 
w/v PEG 8000 and (F) 0.2M Lithium sulfate, 0.1M Tris 8.5, 30 % w/v PEG 4000. 
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did not crack during the incubation were then cryo-protected using 15% w/v glycerol and flash-frozen 
in liquid nitrogen prior to X-ray diffraction experiments that were performed on beamline BM30A at 
ESRF. 
Crystals of the complex 5H2:NHBA-C3 were obtained from a sample at a concentration of 5 mg/mL 
in 0.1 M TRIS pH 8.0 and 1.6 M lithium sulphate. Crystals were cryo-protected in mother liquor 
supplemented with 10% ethylene glycol and flash-frozen in liquid nitrogen prior to X-ray data collection 
experiments that were performed on beamline I02 at the Diamond Light Source, Oxford, UK 
Crystallographic structures determination  
Fabs structures 
Where not specifically stated, all datasets were processed with XDS [105] and with the CCP4 suite 
of crystallographic programs [106], and manual building and refinement were performed using Coot 
[107], Phenix [108], and Buster [109]. 
Crystals of unbound Fab 12E2 diffracted up to 2.7 Å and belonged to space group P21212 with a 
single molecule in the Asymmetric Unit (ASU), with a Matthews coefficient [110]  of 2.66 Å3/Da, for a 
solvent content of 53.8%. The structure of the unbound Fab 12E2 was solved using the automatic 
molecular replacement pipeline MoRDA[111] which automatically selected as search template the 
coordinates of the human anti-human Angiopoietin 2 Fab (PDB 4IMK). Full manual model building and 
refinement of the structure yielded final Rwork/Rfree values of 18.0/26.3 % (Table 2). Excellent and 
continuous electron densities allowed modeling of the 12E1 Fab molecule including residues Gln1-
Lys216 for the H chain, and Glu1-Arg216 of L chain. The final C-terminal six residues of the H chain 
and three residues of the L chain could not be modelled due to lack of electron densities.  
Crystals of unbound Fab 10C3 diffracted up to 1.7 Å and belonged to spacegroup P212121. The 
structure was solved by MR in Phaser [112], using the coordinates of the human anti-HIV-1 clade A/E 
gp120 Fab N5-i5 (PDB 4H8W) as the search model. The refined coordinates of this unbound 10C3 
structure were later used in several attempts to solve the structures of 10C3:NHBA complexed and 
soaked crystals. These attempts were made either by Fourier difference methods [113], where unit 
cell dimensions of the different crystals were isomorphous, or by MR when otherwise. Since no bound 
NHBA or fragments thereof could be observed in the electron density maps of all datasets collected 
from either complexed or soaked crystals, the highest resolution  (1.5 Å) dataset was selected for full 
refinement and to be used for i) the structure analyses presented in this work and ii) the data 
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deposition in the PDB. These crystals belonged to space group P212121, with a calculated Matthews 
coefficient of 2.33 Å3 /Da that is compatible with the presence of one Fab molecule in the ASU (solvent 
content 47.3%). Final coordinates were refined to final Rwork and Rfree values of 18.0% and 21.1%, 
respectively (Table 2), and comprise residues 2–215 of the H chain and 2–211 of the L chain. The 
structure showed excellent electron densities throughout most the Fab chains, except for residues 
belonging to loop 130-134 and to the terminal linker of the H chain. 
Unbound Fab 5H2 crystals diffracted to a resolution of 1.8Å and the diffraction data were 
automatically processed by EDNA framework fast processing system [114] which uses a sequence of 
XDS, XSCALE, Pointless, Aimless, Truncate. The crystals belonged to the monoclinic space group P 
21, and a calculated Matthews coefficient [110] of 2.29 Å3/Da, for a solvent content of 46.3%, 
suggested the presence of three Fab molecules in the ASU (chains H+L, M+N, O+P). The structure of 
unbound Fab 5H2 was solved by molecular replacement using the software package MoRDa [111] 
which automatically selected as templates input coordinates those of the anti-HIV-1 A32 Fab and of 
the anti-integrin LFA-1 FabAL-57 (PDBs 3TNM and 3HI6). The final model was refined to Rwork and 
Rfree values of 18.6% and 22.6%, respectively (Table 2). For the refinement both non-crystallographic 
symmetry (NCS) restraints, and Local Structure Similarity Restraints (LSSR) [109] were used. 
Excellent electron densities could be observed for residues 1-224 and 1-211 of the H and the L 
chains, for residues 2-224 and 1-210 of M and N chains and 1-224 of O chain, respectively. Residues 
49-60 of the light chain P could not be modelled due to lack of density. 
Fab:NHBA complex structure 
Crystals of the 5H2:NHBA-C3 complex diffracted to a resolution of 2.8 Å and belonged to the space 
group P 6122. Two copies of the complex were present in the asymmetric unit with a Matthews 
coefficient of 2.91 Å3/Da and a solvent content of 62.6%. Diffraction data of the 5H2:NHBA-C3 
complex were processed by iMosflm [115] and scaled using AIMLESS in the CCP4 software suite 
[106]. Initial molecular replacement attempts using the program Phaser [116] and input coordinates 
from the antibody 5-51/O12 (PDB 4KMT [117]), with which 5H2 shared 82% sequence identity, and 
single models from the NMR structure 2LFU, failed. However, when the template coordinates for the 
Fab were substituted with those from the unbound 5H2 structure solved here, molecular replacement 
in Phaser gave a correct solution with the structure of the complex Fab 5H2:NHBA-C3, which was 
later refined to final Rwork and Rfree values of 19.2% and 23.8% (Table 8). NCS torsion-angle restraints 
[108] were used in the refinement of 5H2:NHBA-C3 complex, and excellent electron densities could be 
observed for almost the entire complex (residues Met290-Asp405 for NHBA-C3, residues Gln1-
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Cys226 and Glu1-Glu212 for the Fab 5H2 H and L chain, respectively). The only regions that could 
not be modelled due to lack of electron density were those of residues 88-90 and of the C-terminal 
His-tag of both NHBA-C3 molecules present in the ASU. 
X-ray structure analysis 
The quality of all the final refined models described in this study was assessed using MolProbity 
[118]. Fab elbow angles were calculated with phenix.fab_elbow_angle [108] and protein-protein 
interface areas were analysed and calculated using the Protein Interfaces, Surfaces and Assemblies 
service (PISA) available at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-
srv/prot_int/pistart.html, [119]). Pairwise structural comparisons of unbound-5H2 molecules (chains 
HL, MN, OP) with bound-5H2 (chains HL, IM), NHBA-C3 (chains A, B) and NHBA-C1 (PDB entry: 
2LFU [64]) were performed using the Secondary Structure Matching (SSM) algorithm within Coot 
[107]. Electrostatic potentials were calculated using the APBS PyMOL plugin [120]. Figures were 
generated using PyMOL (http://www.pymol.org). Alignments were generated with ALINE [121]. 
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NHBA sequences 
• NHBA-NZ p2 (Uniprot accession number Q9JPH1) 
MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLSKPAAPVVSEKETEAKEDAPQAGSQG 
QGAPSAQGGQDMAAVSEENTGNGGAAATDKPKNEDEGAQNDMPQNAADTDSLTPNHTPAS 
NMPAGNMENQAPDAGESEQPANQPDMANTADGMQGDDPSAGGENAGNTAAQGTNQAENNQ 
TAGSQNPASSTNPSATNSGGDFGRTNVGNSVVIDGPSQNITLTHCKGDSCSGNNFLDEEV 
QLKSEFEKLSDADKISNYKKDGKNDGKNDKFVGLVADSVQMKGINQYIIFYKPKPTSFAR 
FRRSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAEKLP 
GGSYALRVQGEPSKGEMLAGTAVYNGEVLHFHTENGRPSPSRGRFAAKVDFGSKSVDGII 
DSGDGLHMGTQKFKAAIDGNGFKGTWTENGGGDVSGKFYGPAGEEVAGKYSYRPTDAEKG 
GFGVFAGKKEQD 
• NHBA-MC58p3 (Uniprot accession number Q9JQW0) 
MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLSKPAAPVVSEKETEAKEDAPQAGSQG 
QGAPSAQGSQDMAAVSEENTGNGGAVTADNPKNEDEVAQNDMPQNAAGTDSSTPNHTPDP 
NMLAGNMENQATDAGESSQPANQPDMANAADGMQGDDPSAGGQNAGNTAAQGANQAGNNQ 
AAGSSDPIPASNPAPANGGSNFGRVDLANGVLIDGPSQNITLTHCKGDSCSGNNFLDEEV 
QLKSEFEKLSDADKISNYKKDGKNDKFVGLVADSVQMKGINQYIIFYKPKPTSFARFRRS 
ARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAEKLPGGSY 
ALRVQGEPAKGEMLAGAAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSVDGIIDSGD 
DLHMGTQKFKAAIDGNGFKGTWTENGSGDVSGKFYGPAGEEVAGKYSYRPTDAEKGGFGV 
FAGKKEQD 
• NHBA-2996 p20 (Uniprot accession number Q9JPP1) 
MFERSVIAMACIFALSACGGGGGGSPDVKSADTLSKPAAPVVAEKETEVKEDAPQAGSQG 
QGAPSTQGSQDMAAVSAENTGNGGAATTDKPKNEDEGPQNDMPQNSAESANQTGNNQPAD 
SSDSAPASNPAPANGGSNFGRVDLANGVLIDGPSQNITLTHCKGDSCNGDNLLDEEAPSK 
SEFENLNESERIEKYKKDGKSDKFTNLVATAVQANGTNKYVIIYKDKSASSSSARFRRSA 
RSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSGNIFAPEGNYRYLTYGAEKLPGGSYA 
LRVQGEPAKGEMLAGTAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSVDGIIDSGDD 
LHMGTQKFKAAIDGNGFKGTWTENGGGDVSGRFYGPAGEEVAGKYSYRPTDAEKGGFGVF 
AGKKEQD 
• NHBA-C3 p20 
MASMLAGTAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSVDGIIDSGDDLHMGTQKF 
KAAIDGNGFKGTWTENGGGDVSGRFYGPAGEEVAGKYSYRPTDAEKGGFGVFAGKKEQDL 
EHHHHHH 
• NHBA-114-332 p2 
MPNHTPASNMPAGNMENQAPDAGESEQPANQPDMANTADGMQGDDPSAGGENAGNTAAQGT 
NQAENNQTAGSQNPASSTNPSATNSGGDFGRTNVGNSVVIDGPSQNITLTHCKGDSCSGN 
NFLDEEVQLKSEFEKLSDADKISNYKKDGKNDGKNDKFVGLVADSVQMKGINQYIIFYKP 
KPTSFARFRRSARSRRSLPAEMPLIPVNQADTLIVDGEALEHHHHHH 
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NHBA production and characterization 
NHBA full length contains predicted partially unfolded regions 
Bioinformatics analyses were performed on a panel of long NHBA sequences (p1, p2, p3, p5, p29) 
to predict putative regions of disorder and to expand the analysis previously performed only on the 
short NHBA p20 sequence [64]. The Phyre2 [92] suite of tools for secondary structure prediction 
indicated a substantial lack of secondary structures elements in the region covering the first ~250 
amino acids of NHBA (N-terminal domain), while the predictions for residues spanning from 341 to 
492 (C-terminal domain) are in agreement with the presence of β secondary structures elements as 
observed in the experimentally-determined NMR structure (PDB 2LFU) [64](Fig. 3.1). Comparable 
outputs were obtained by using other secondary structure prediction tools such as SABLE [94], 
PSIPRED [95] and JPred4[96] (Fig. 3.1). Consistently, methods for the prediction of disorder (IUPred 
[98] and MeDor [99]) as well as of protein dynamics prediction (DynaMine [97]) indicated that the first 
200 amino acids of NHBA are extremely flexible (Fig. 3.2). In agreement with these predictions, the 
NHBA N-terminal domain is enriched in charged and hydrophilic residues, which, as previously 
reported, is a common feature of intrinsically disordered proteins (IDPs) [122-124]. Moreover, these 
sequence-based predictions also suggest the presence of secondary structure elements (α-helices 
and β-strands) for the region made of residues ~240-340. It can be hypothesized that these 100 amino 
acids preceding the β-barrel can acquire a transient and context dependent secondary structure, 
similarly to other IDPs that fold transiently in the presence of specific interactors or under certain 
environmental conditions, in order to perform their biological function [122, 125-127].  
Interestingly, it was previously shown how predictions of protein disorder for regions longer than 40 
residues give less than 6% of false positives [128].  
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Figure 3.1. NHBA p2 secondary structure predictions.  Outputs of secondary structure predictions on NHBA 
p2 sequence performed with Phyre2, SABLE, PSIPRED and JPred are summarized in the figure. 
 
 
Figure 3.2. NHBA p2 disorder predictions. The outputs from the analyses performed with Disopred and with 
Dynamine are shown in A and B. 
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Production and characterization of protein constructs for structural studies 
In order to gain molecular insights into the NHBA 3D organization, we sought to determine its X-
ray structure using full length and sub-full length constructs, both alone and in complex with human 
Fabs. To perform crystallographic studies, high amount of pure proteins are needed, therefore 
recombinant NHBA constructs were produced in E. coli and purified as described in the Materials and 
Methods, yielding highly pure samples as shown by SDS-PAGE (Fig. 3.3A). While the band for the 
NHBA-C3 sample corresponded to the expected molecular weight (MW) of ~13kDa, both the NHBA 
p2 and NHBA-114-332 samples were observed to run at higher MW (~62kDa and ~38kDa, 
respectively) with respect to their calculated theoretical values (49.9kDa and 24kDa). In agreement, 
samples of NHBA p2 and NHBA-114-332 showed anomalous SEC profiles, eluting in correspondence 
of significantly higher MW than expected (~170kDa and ~55kDa, respectively) (Fig. 3.3A). Therefore, 
further analyses were performed on these samples by analytical size-exclusion high-performance 
liquid chromatography (SE-HPLC) coupled with multi-angle laser light scattering (MALLS), which 
showed how NHBA p2 presented a single species ≥ 97% pure with an absolute molecular mass of 51 
kDa while NHBA_114-332 presented similar purity and an absolute molecular mass of 24 kDa (Fig. 
33B). Therefore, both purified proteins were monomeric in solution, despite their anomalous properties 
both in SDS-PAGE and in SEC. Generally, hydrodynamic techniques such as size exclusion can aid in 
identifying IDPs, since they report on the radius of the protein which for IDPs is often larger than 
expected [129]. In conclusion, the behavior of constructs NHBA p2 and 111-342 during the purification 
seems in agreement with the previously predicted high flexibility and/or disorder of their N-terminal 
region [130].  
To further characterize putative disorder in NHBA, and since protein stability often correlates with 
crystallization propensity [131], the thermal stability of NHBA was studied using differential scanning 
calorimetry (DSC). While NHBA full length (p2) presented two distinct peaks corresponding to melting 
temperature (Tm) transitions at 54.0 and 97.1 °C, the N- and C-terminal constructs (NHBA-114-332 
and NHBA-C3) showed only one single Tm, at 56 or 88°C, respectively. These results suggested that 
the C-terminal domain of NHBA, previously shown to fold as a well-structured β-barrel [64] is 
significantly more thermo-stable than the N-terminal region, where instead the lower Tm of the N-
terminal domain agrees well with the predicted lack of fully structured regions. 
Both purified samples of NHBA p2 and NHBA_114-332 were used to set up several crystallization 
trials as described in Materials & Methods, but these experiments did not yield crystals suitable for 
further structural studies.  
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Human Fabs production and characterization 
Fragments antigen binding (Fabs) used in this study were purified using three chromatographic 
steps (see Materials and Methods), and the same purification protocol was applied to all three Fabs 
studied (10C3, 12E1, and 5H2) with no noticeable differences in the behavior and final quality levels of 
the purified samples. This protocol allowed achieving high amounts of purified Fab samples, with final 
average yields of 6 mg of Fabs from expression culture media of 100 ml in volume. Only one 
representative example of a Fab purification is described below. 
SEC elution profiles of the Fabs consisted in a single symmetric peak with a retention time 
corresponding to an apparent molecular weight of ~35kDa (Fig 3.4). The purity of the Fabs was also 
checked by SDS–PAGE both in reducing and non-reducing conditions. As expected, while under 
reducing conditions distinct bands could be distinguished corresponding to the single Fab heavy and 
 
Figure 3.3. Purification and characterization of NHBA and NHBA constructs. (A) Overlay of size-exclusion 
chromatography profiles of purified NHBA samples. Above each peak the corresponding apparent molecular 
weight determined by calibration of the column using standard molecular weight markers (Bio-rad) is reported. 
The eluted material was run on a SDS-PAGE gel under non-reducing conditions (inset). (B) Table reporting the 
SEC-MALLS results for the determination of the elution time on an analytical column, the absolute molecular 
weight and polydispersity of NHBA p2 and NHBA_114-332 samples. In both cases, the MALLS data clearly 
indicated a single monodisperse species with an absolute molecular weight corresponding to their respective 
monomeric form. (C) DSC profiles of NHBA samples with the relative Tm associated to each peak. The first 
transition is associated to the N-ter unfolding and the second to the C-ter unfolding. Samples are colored as 
follows: NHBA p2 in blue, NHBA_114-332 in magenta, and NHBA-C3 in green.  
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light chains, under non-reducing conditions a single band was detected at ~49kDa, which corresponds 
to a Fab heterodimer (Fig 3.4). The homogeneity of the purified Fabs were also confirmed by 
analytical SEC, which revealed a single symmetrical peak eluting at an apparent molecular weight of 
35kDa, in agreement with the elution from the preparative SEC. 
 
Fab:NHBA interactions studies 
Mapping of the binding of Fabs 12E1, 10C3, and 5H2, to NHBA, has been performed by protein 
chip and it has been recently published [90]. This study showed how 12E1 recognizes a stretch of N-
terminal residues of NHBA, while Fab 10C3 binds to an N-terminal region immediately before the 
boundary with the C-terminal domain, and 5H2 recognizes the full C-terminal domain. To further 
investigate the binding between the Fabs and NHBA, affinity constants and binding kinetics were 
calculated by surface plasmon resonance (SPR), performing single-cycle kinetics experiments (SCK). 
Three representative variants of NHBA were selected: two long (p2, the vaccine variant [13], and p3, 
the first N. meningitidis serogroup B sequenced strain [8]) and one short (p20, from which the NHBA-
C3 construct was designed). These experiments showed that NHBA p2 and p3 are recognized by 
                    
Figure 3.4. Purification of Fab 10C3. (A) Preparative size-exclusion chromatography profile of Fab 10C3. (B) 
Eluted fractions analyzed by SDS-PAGE under non-reducing (upper panel) and reducing (lower panel) conditions. 
A single band corresponding to the dimeric Fab is observed under non-reducing conditions; two separates bands 
corresponding to Fab HC and LC are observed under reducing conditions, where disulfides and inter-molecular 
bonds are disrupted by DTT and heat treatment. Similar results were obtained for 12E1 and 5H2. 
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Fabs 10C3, 12E1 and 5H2 with high affinities (pico to nano molar range) (Table 1). In particular, Fab 
5H2 showed overall the highest binding affinity for all the tested NHBA variants.  
The SPR results are also in agreement with the previously reported epitope mapping studies [90, 
91] (Fig. 3.5). Specifically, SPR confirms that Fab 5H2 recognizes the conserved C-terminal β-barrel 
of NHBA, likely by binding to a very conserved epitope as inferred from its ability to recognize with 
high and comparable affinities all the variants tested (see for further details the results on section 
NHBA β-barrel conservation and 5H2 cross-reactivity, and Fig. 3.24). Similar considerations can be 
made for Fab 12E1, which maps onto the NHBA N-terminal domain and recognizes a conserved 
putative linear epitope. Finally, Fab 10C3 recognized both the long variants p2 and p3 but did not bind 
the short variant p20. A fully conserved region between NHBA p2 and p3 (Fig 3.5) that is not fully 
conserved in p20 could help explain the specificity of Fab 10C3 and define a “core epitope” to 
residues 243-KSEFEKLSDADKISNYKKDG-262.  
 
Structural characterization of human Fabs and of a NHBA-Fab complex 
Human Fab 12E1 
Crystals of unbound Fab 12E1 diffracted X-rays to a resolution of 2.7 Å. A full data set was 
acquired from a single 12E1 crystal fragment isolated from a cluster of plates and used for successful 
structure determination by molecular replacement (see Material and Methods and Table 2). The 
overall architecture and fold of the 12E1 Fab structure is consistent with the canonical β-sandwich 
immunoglobulin fold composed by two chains (H and L) and four domains (VL, CL, VH and CH, where 
 
Figure 3.5. Epitope mapping studies of NHBA p2. (A) The top boxes show a schematic representation of 
NHBA p2, with colored lines referring to the regions of the 12E1 epitope (blue), 10C3 (green), and 5H2 (grey) as 
reported in 90 91(B) The amino acid sequences of the 12E1 (left) and 10C3 (right) epitopes for variants p2, p3, 
and p20, are aligned. Identical (*), conserved (:) and semiconserved (.) residues are indicated below the 
alignment. 
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L indicates light chain, H heavy chain, V variable domain and C constant domain) (Fig. 3.6), with four 
pairs of disulfide bridges that link residues Cys22-Cys96 in the VH and Cys142-Cys198 in the CH, and 
residues Cys23-Cys93 and Cys139-Cys199 in the VL and CL respectively The structure was analyzed 
with PISA (Protein Interfaces, Surfaces and Assemblies [119]) , which revealed an interaction surface 
between the H and L chains of 1735.5 Å2, and the presence of 10 intermolecular hydrogen bonds 
(Table 3). 
 
To analyze and annotate the putative paratope of 12E1, the definition of CDRs as given by North et 
al. was used [79]. In this work, the classification of CDR “canonical” conformations [77, 78] have been 
recently revisited in light of the larger amount of antibody structural information available nowadays 
with respect to the canonical classifications that were originally introduced in the late 1990s. 
Therefore, this work now provides an enhanced and more detailed classification, resulting in revisited 
clustering of the structures of CDR loops. According to this new definition, regions of the 
Ramachandran plot that define CDRs clusters by conformation are annotated as follows: B for β-sheet 
region, P for polyproline II, A for α-helix, D for δ region (near α-helix but at more negative values of ϕ), 
 
Figure 3.6. Fab 12E1 crystal structure. (A) Overall structure of Fab 12E1. The light (L) and heavy chains (H) 
are colored in light and dark grey respectively. CDR-L1and CDR-H1are colored in yellow, CDR-L2 and CRD-H2 
are colored in green, CDR-L3 and CDR-H3 are shown in blue. Disulfide bonds are depicted with magenta sticks 
(B) Surface representation of a zoomed view of the 12E1 CDRs forming a concave surface at the interface 
between heavy and light chain. 
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L for left-handed helix, and G for γ region (ϕ>0° excluding the L and B regions) (see Fig 4 in reference 
[79]). 
 
In the H chain of 12E1, the CDR-H1 is made of residues Lys23–His35 and belongs to the cluster 
H1-13-1 with loop conformation PPBLBPAAABPBB, while the CDR-H2 is made of residues Trp50–
Lys59, and belongs to cluster H2-10-1 with loop conformation BBPAADLPBB. Finally, the CDR-H3 is 
formed by Ile97-Pro104 (loop conformation BPAGLLBp) with the anchor region not clearly belonging 
to any of the classes defined by North et al (Fig. 3.7A). In the L chain, residues Arg24–Asn39 form a 
remarkably long CDR-L1 that falls within the L1-16-1 cluster and with loop conformation 
BPBLPBPAPLLPPBBPB, while the CDR-L2 is made of residues Tyr54–Ser61 and is within the L2-8-1 
cluster and loop conformation BLLDPPPP. The CDR-L3 is made of residues Met94–Thr102 with 
conformation similar to the L3-9-cis7-1 cluster and loop conformation BBDABPpPB (Fig. 3.7B). 
The overall architecture of the putative paratope shows a concave topology, with a deep groove at 
the interface between heavy and light chain delimited by the CDR-H3 on one side and by all of the 
CDR-Ls on the other side (Fig. 3.6B), with the CDR-L1 being the region that protrudes the most. The 
CDRs region has a calculated accessible surface area (ASA) of ~3,850 Å2, as obtained with PISA 
[119]. The most abundant residues forming the exposed surface are Lys (13.35%), Arg (11.74%), Ser 
(9.83%), Tyr (9.70%), and Asn (7.56%) (Table 4). While the enrichment with aromatic residues and 
Ser of Fab paratopes is in agreement with other antibody paratope surfaces previously described [75, 
132-135], the location of Ser on the surface of Fab 12E1 appears to be mostly peripheral, while Tyr 
and Trp are more equally distributed (Fig. 3.8A). A more noticeable feature of the 12E1 structure is 
the presence of a high number of positively-charged residues in the proximity of the putative paratope, 
mainly Arginine and Lysine that together form 28.8% of the entire paratope surface accessible area 
 
Figure 3.7. 12E1 CDR regions. CDRs for the variable heavy chain (Top) and for the variable light chain 
(Bottom) are shown with highlights over the sequence, while loop conformations are shown below the sequence, 
and secondary structures for each residue are shown above. Lower-case letters in loop conformation indicate cis 
residues. 
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(Table 4). This feature is not common among other Fabs, as long-chain hydrophilics are not frequently 
found in antibody paratopes [136], and it suggests a possible role in the recognition of NHBA (Fig. 
3.8B). Also, the presence of these positively-charged patches in the paratope of 12E1 allows one to 
speculate on the apparently good complementarity with the overall acidic nature of the 10-residue 
epitope previously  mapped (residues AAVSEENTGN [91]). 
 
Additionally, attempts of co-crystallizing 12E1 in complex with NHBA p2 were performed but did not 
yield crystals, while the low quality and number of crystals obtained for the unbound 12E1 did not 
allow to pursue further soaking experiments with epitope peptides.   
Human Fab 10C3  
Crystals of unbound Fab 10C3 were obtained under a variety of conditions (Table 5, group 1), 
resulting in 7 initial complete X-ray diffraction datasets that were collected at resolutions between 1.7 
and 2.2 Å. Among these, dataset #7 (Table 5), which diffracted at the highest resolution (1.7 Å), was 
selected for structure determination by MR (see Materials and Methods). The refined structure of 
unbound 10C3 was then used as a template to solve the structures of all the other 6 datasets either by 
Fourier difference methods [113], where unit cell dimensions were isomorphous, or by MR when not 
isomorphous. These refined coordinates were also later used as the model input template for attempts 
at solving the structure of the 10C3:NHBA complex by MR.  
 
Figure 3.8. 12E1 CDRs detailed view. (A) Top view of the 12E1 CDR region, with the most represented residues 
colored in orange for Trp and Tyr, in blue for Lys and Arg, and in green for Ser. A dotted line separates HC from 
LC. (B) Same view as in A, with the electrostatic potential mapped onto the CDRs surface. The electrostatic 
potential distribution was calculated with APBS 120, where red and blue surfaces show negative and positive 
charges as contoured in the range from –3 kBTe-1 (red) to +3 kBTe-1 (blue), while white surfaces show neutral 
potentials. 
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High resolution epitope mapping of the binding of Fab 10C3 to NHBA was attempted by performing 
a number of co-crystallization experiments of NHBA-10C3 complexes, as well as by soaking NHBA 
derived peptides onto crystals of unbound Fab 10C3. First, size exclusion chromatography was used 
to isolate complexes formed between Fab 10C3 and constructs NHBA_p2 or NHBA_114-332. The 
chromatographic profiles of the complexes showed in both cases one peak corresponding to the 
complexes 10C3:NHBA_p2 (apparent MW ~170kDa, calculated MW 96.2kDa) or 10C3:NHBA_114-
332 (apparent MW ~85kDa, calculated MW 71.2kDa) and a second peak corresponding to the excess 
unbound Fab 10C3 at an apparent molecular weight of ~35kDa (calculated MW 46.3kDa) (Fig. 3.9). 
To explain the apparent molecular weights that were not in close agreement with those calculated, we 
performed SDS-PAGE on the eluted fractions in reducing conditions, which confirmed how in both 
cases the first peak contained both NHBA and 10C3, while the second peak contained Fab only. This 
was also in agreement with an overlay of elution profiles of NHBA_p2, 114-332, and 10C3 derived 
from separate runs (Fig. 3.9). Importantly, as already discussed above and as previously reported 
[130], purified NHBA samples eluted at apparent molecular weights larger than expected. Also, in a 
separate run unbound Fab 10C3 eluted after ~84.75.mL, but it could also be detected by SDS-PAGE 
in fractions belonging to the putative complexes that were eluting either at ~65 mL or ~73 mL. These 
results strongly suggest that both the complexes 10C3:NHBA_p2 and 10C3:NHBA_p2_111-332 were 
successfully formed and isolated.  
 
 
 
Figure 3.9. Fab10C3:NHBA complex formation. Top: SEC profiles of complexes 10C3 :NHBA p2 (A) and 
10C3:NHBA_114-332 (B). Bottom:  corresponding fractions run on SDS-PAGE gel. The first peak represents the 
complex (green) while the second peak is for the unbound Fab 10C3 (red box). Independent SEC runs: NHBAp2 
(magenta), NHBA_113-332 (orange), 10C3 (grey). Retention volumes are indicated above each peak. 
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The purified complexes were concentrated and used to set up a number of crystallization 
experiments that were performed using different crystallization conditions, different sample 
concentrations, as well as using in-situ proteolysis in order to rid the samples of putative disordered 
regions that might hinder crystallization [104, 137]. Strikingly, only crystallization trials of the 
10C3:NHBA_p2 complex and after in-situ proteolysis yielded crystals after ~60 days of incubation at 
20°C, and under different crystallization conditions (Table 5, group 2). Six datasets of these putative 
10C3:NHBA complexes were collected and their structures solved by MR using the refined 
coordinates of the unbound 10C3 (dataset #7) as search template. Disappointingly, despite the high 
binding affinity between Fab 10C3 and NHBA (3.8x10-9 M, Table 1), none of the electron density maps 
calculated from these structures revealed the presence of a bound NHBA molecule in the Asymmetric 
Unit (ASU). Among other possible factors, this might be attributed also to the proteolytic process 
required to obtain these crystals, which might have affected the integrity of NHBA and thus induced its 
dissociation, or the complex might have dissociated due to the influence of the crystallization 
conditions. 
Additional experiments were performed to obtain the structure of the NHBA epitope bound to Fab 
10C3 by soaking a 17-residue long NHBA-derived peptide (made of residues 244-
SEFEKLSDADKISNYKK-260) onto crystals of the unbound Fab. This peptide was designed starting 
from previous information derived from the epitope mapping by HDX-MS [90]. Although these soaked 
crystals diffracted X-rays at high resolution (Table 5, group 3), electron density maps calculated from 
several datasets again did not reveal a bound peptide (Fig. 3.10). The lack of bound peptide in the 
crystals of 10C3 might be due to several factors, such as: i) the physico-chemical properties of the 
synthesized peptide; ii) the peptide size/length that might have affected its ability to migrate through 
the crystal channels; iii) the lack of more precise information on the exact residues required for 
binding, which might have resulted in a putative sub-optimal design of the peptide; and iv) the 
likelihood of more conformational requirements (see antigen context) for 10C3 recognition.  
Overall, these experiments resulted in additional 8 structures of unbound Fab 10C3 (Table 5, 
groups (2) and (3)), with dataset #15 being the one at the highest resolution (1.5 Å). Therefore, 
structure from dataset #15 was fully built and refined (Table 2) with the aim to use it for the analyses 
presented below (being at the highest resolution and thus presenting the highest level of structural 
details), as well as for the coordinates deposition in the PDB (in progress). 
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The overall structure of the Fab 10C3 presents the typical IgG fold (Fig. 3.11), stabilized by a total 
of four pairs of well-defined disulfide bridges located in the constant domains between residues 
Cys137 and Cys197 of the LC, and Cys142 and Cys198 of the HC. Disulfide bonds are also found in 
the variable domains between residues Cys22 and Cys90 of the LV, and Cys22 and Cys96 of the HV. 
The interface of the H and L chains of 10C3 has a total surface area of 1,491 Å2, 10 hydrogen bonds, 
and 5 salt bridges (Table 6). The CDRs of Fab 10C3 were annotated, as for Fab 12E1, using the 
definition and nomenclature recently introduced by North et al. [79] (Fig. 3.12). The CDR-H1, made of 
residues Lys23-His35, falls within the H1-13-1 cluster and perfectly matches the loop conformation 
PPBLPAAABPBB; the CDR-H2 is made of residues Trp50-Asn59, falls into the H2-10-1 cluster and 
has a loop conformation BBPDDDLPBB; the CDR-H3 (Ala96-Tyr103) belongs to the H3-7-1 cluster 
with a loop conformation BPGADLAB. In the light chain, the CDR-L1, made of residues Thr23-Ser36, 
belongs to a L1-14-2 cluster, with loop conformation BBBAADAADBDPPB. The CDR-L2 comprises 
residues Tyr51-Ser58, lies within the L2-8-1 cluster and has a loop conformation BLLDPPPP, while 
the CDR-L3 is made of residues Ser91-Val100 and has a loop conformation BBPDGLLPPB, which is 
similar to those of the L3-10-1 cluster.  
  
Figure 3.10. 2Fo-Fc electron density maps (HC: dark blue, LC: light blue) contoured at 1σ show the well-defined 
regions of the CDRs of 10C3 and lack of extra densities for a putative bound partner. 
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Figure 3.11. Structure of unbound Fab 10C3. (A) The overall structure of Fab 10C3 is shown, with the light and 
heavy chains colored in blue and gold, respectively. CDR-L1 and CDR-H1 are colored in yellow, CDR-L2 and 
CRD-H2 in green, CDR-L3 and CDR-H3 are in blue. Disulphide bonds are depicted with magenta sticks. (B) 
Surface representation of a zoomed view of the 10C3 CDRs region. 
 
Figure 3.12. 10C3 CDR regions. CDRs for the variable heavy chain (Top) and for the variable light chain 
(Bottom) are shown with highlights over the sequence, while loop conformations are shown below the sequence, 
and secondary structures for each residue are shown above.  
49 
 
 
The total solvent exposed surface of the 10C3 CDRs has an area of ~3,600 Å2, and it is dominated 
by polar uncharged amino acids that cover ~46% of the total accessible surface area (Table 7). Within 
the CDRs, a prevalence of Asn (15.17%) and of hydroxyl side-chain-containing residues like Ser 
(19.9%) and Thr (10.56%) can be observed, in agreement with previous studies on the typical 
composition of antibody paratopes (Table 7) [75, 133, 135]. These residues are clustered in the loop 
regions of CDR-H1, CHR-H2, CDR-L1 and CDR-L3 and contribute, along with several Tyr residues, to 
create a rim around a central positively-charged cavity at the interface between the H and L chains 
(Fig.3.13A and B). In addition, residues Asp101 and Asp103 from the CDR-H3 and Glu52 of CDR-L2 
provide the paratope with a negatively charged area (Fig. 3.13B). Finally, several Tyr are solvent 
exposed, covering up to 11.71% of the ASA, and surrounded by short-chain hydrophilic amino acids 
(Asp, Asn, Ser, Thr). 
 
 In an attempt to speculate on the binding of 10C3 to NHBA, the paratope composition analyzed 
above can be related with the physicochemical properties of the 10C3 putative epitope previously 
identified by HDX-MS [90], which is made of a linear 32-residue sequence (243-
KSEFEKLSDADKISNYKKDGKNDGKNDKFVGL-274). This region is localized in the N-terminal region 
of NHBA that is characterized by the absence of clearly predictable secondary structures, but with a 
 
Figure 3.13. Structure of Fab 10C3. (A) Top view of the Fav 10C3 CDR region, with the most represented 
residues colored orange for Tyr and Trp and green for the polar Ser, Thr and Asn. A dotted line separates HC 
from LC.  (B) Same view as in A, showing the surface of the CDRs colored according to the electrostatic potential 
distribution, which was calculated with APBS 120, where red and blue surfaces show negative and positive 
charges as contoured in the range from –3 kBTe-1 (red) to +3 kBTe-1 (blue), while white surfaces show neutral 
potentials. 
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putative slight tendency to acquire alpha-helical conformation (see NHBA full length contains predicted 
partially unfolded regions and Fig.3.1A). This segment is particularly rich in charged residues, 
especially Lys and Asp, which agrees with the presence of exposed positive and negative patches 
observed in the paratope surface (Fig. 3.13B). The latter suggests that electrostatic interactions could 
play a significant role in NHBA recognition by 10C3, a feature that has been already described as key 
specifically for antibody recognition of IDPs [136, 138]. 
Finally, the degree of similarities between the 15 unbound 10C3 structures was analyzed by 
performing superpositions of all the solved structures against the final high-resolution and fully refined 
coordinates of the reference dataset (#15). Using the secondary structure matching (SSM) algorithm 
within Coot [107], we aligned the Cα atoms of each solved structure (datasets #1 to #14) against the 
reference structure (dataset #15) and calculated the root mean square deviations (rmsd) value for 
each alignment (Table 5, column VII). The maximum rms deviations were observed for datasets #2 
and #6, which diverged from the reference model with rmsd values of 1.01, and 0.97 Å, respectively, 
while the most superimposable structure (#7) had an rmsd value of 0.23 Å. Overall, these 
superpositions did not reveal significant differences in the 10C3 fold nor in the CDR arrangements 
(Fig 3.14A and B). Remarkably, also the distribution of side-chain rotamers for residues making the 
CDRs resulted conserved among all the structures compared. The only exceptions were residues 
His57 and Tyr104, localized in the CDR-H2 and the framework regions, respectively (Fig. 3.14C). In 
summary, a high degree of isomorphism was observed among all 15 structures of unbound Fab 10C3 
described here (Table 5), although these were obtained from crystals grown in different crystallization 
conditions, made of different salt composition (i.e. sodium chloride, ammonium sulfate, calcium 
chloride, magnesium chloride, potassium thiocyanate) and concentrations, pH values (ranging from 
pH 4.2 to pH 6.5), and other precipitants and buffers (Table 5). These were virtually identical, with 
space group (P212121), and with nearly identical cell parameters. This noticeable structure 
reproducibility has already been reported for other Fabs [139], and it highlights the extreme stability 
and rigidity of the Fab 10C3, an observation that agrees with the intrinsic and general structural 
stability of Fabs [78]. 
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Human Fab 5H2 
The 1.8 Å crystal structure of Fab 5H2 displays the canonical sandwich immunoglobulin fold, 
similarly to those of the other Fabs studied here. Secondary structure superpositions among the three 
molecules that were observed in the ASU of the 5H2 crystals (chains for each heavy and light 
heterodimer named HL, MN, and OP), resulted in an rmsd value of 0.50 Å between copy HL and MN, 
and of 2.1 Å between HL and OP (Fig. 3.15).  
Annotation of the Fab 5H2 CDRs was made based on the classification already used above for 
Fabs 12E1 and 10C3 [79]. The heavy chain CDR-H1 (residues Thr23-Thr37) belongs to a H1-15-1 
cluster with loop conformation PBBLBPAAPPABBPB, the CDR-H2 (residues Tyr52-Lys60) belongs to 
cluster H2-9-1 and adopts a loop conformation BBPAALPBB, while the CDR-H3 (Ala98-Phe112) was 
assigned to the H3-7-1 class defined by North et al. [79] having BPPPBAADGBBPAB as loop 
conformation. In the L chain, the CDR-L1 (residues Arg24-Asn34) belongs to cluster L1-11-1 and 
adopts loop conformation BPABPDGDPBB, whereas the CDR-L2 (residues Tyr49-Ser56) and the 
CDR-L3 (residues Glu89-Thr96) belong respectively to clusters L2-8-1 and L3-8-1, with loop 
conformations BLLDPPPP and BDPABPPB (Fig. 3.16).  
 
Figure 3.14. Structural alignment of all 10C3 structures. (A) All 10C3 structures solved in this work are shown 
as ribbon after superposition, and colored in black and white for the heavy (H) and light (L) chains. (B) Two highly 
divergent apo-10C3 structures are depicted as ribbons (structures from datasets #6 and #15), and colored as in 
(A). Regions of maximum divergence between Cα of the two structures are shown with magenta lines. (C) Zoom 
into the regions where differences in the position of side chain rotamers could be observed. 
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Figure 3.15 ASU content of the unbound 5H2 structure. The overall arrangement of the three copies of 5H2 is 
shown, and chains are labelled. Copy MN is colored in yellow (Light chain) and orange (Heavy chain), copy OP is 
colored in lime (Light chain) and green (Heavy chain), copy OP is colored in salmon  (Light chain) and raspberry 
(Heavy chain). 
 
 
Figure 3.16. Fab 5H2 CDRs region. CDRs for the variable heavy chain (Top) and for the variable light chain 
(Bottom) are shown with highlights over the sequence, while loop conformations are shown below the sequence, 
and secondary structures for each residue are shown above.  
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Complex 5H2:NHBA-C3 
Structure determination 
The structure of the complex between Fab 5H2 and the C-terminal region of NHBA (construct 
NHBA-C3) was solved at 2.8 Å resolution (Table 8). Two copies of the complex were present in the 
ASU, disposed orthogonally to each other (Fig 3.17A). Structural superposition of these two copies of 
the complex resulted in an rmsd value of 0.43 Å for 544 aligned Cα atoms (from a total of 548 Cα 
atoms), therefore indicating very high similarity throughout all chains. For this reason, only one copy 
(chains HL) will be used for the description of the structure below. 
 
 
 
Figure 3.17. Structure of the complex 5H2-NHBA-C3. (A) The two copies of the complex are depicted with the 
5H2 chains HL colored blue/green and chains IM colored violet/palegreen. NHBA molecules binding to HL and IM 
are colored magenta and raspberry, respectively. (B) Side view of the copy HL:NHBA-C3, with the epitope 
surface colored in grey. (C) Front view of NHBA-C3, with the 5H2-interacting interface colored in grey. Blue and 
green tubes show the 5H2 CDRs, while the rest of the Fab is omitted for clarity. 
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Structure analysis and details of the 5H2 epitope recognition 
The overall structure of the complex readily illustrates how Fab 5H2 recognizes a conformational 
epitope made of an entire face of the C-terminal β-barrel of NHBA through extensive interactions 
mediated by both the Fab H and L chains (Fig 3.18). NHBA-C3 is folded as an eight-stranded 
antiparallel β-barrel connected by seven loops of variable lengths, an architecture shared with other N. 
meningitidis proteins such as fHbp and TbpB [64], and also consistent with the previously determined 
NMR structure of an NHBA construct made of residues 245-427 [64] (PDB 2LFU). Structural 
superpositions of the NHBA-C3 structure from the complex determined here with each one of the ten 
NMR models deposited (PDB 2LFU) revealed an average rmsd of 1.85 Å, considering equivalent Cα  
atoms, with the highest rmsd corresponding to 2.62Å and the lowest to 1.58Å. The major differences 
could be observed in the loops, suggesting local inherent flexibility. However, the NMR models 
showed an average rmsd of 1.36Å when compared among themselves, in agreement with structural 
differences especially in the most N-terminal region of the 2 stranded β-sheet, which has coordinates 
not univocally assigned. These local variability in the NMR model could be attributed either to the 
inherent lower precision of the technique as compared to crystallographic structures, or to the sample 
environment (in solution). 
 
 
Figure 3.18. Polar contacts between 5H2 and NHBA-C3. (A) The 8-stranded β-barrel organization of NHBA-
C3 and the surface of the 5H2 epitope are shown. A yellow dotted line splits the regions recognized by HC (top) 
and LC (bottom). (B) Top and bottom panel show the network of polar interactions between the HC or LC of Fab 
5H2 and NHBA-C3. (C) Detail of the salt bridge between NHBA Arg339 and 5H2 Asp100.  
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The interface between NHBA-C3 and Fab 5H2 buries a total of  ~1,700 Å2 of surface area, split in 
~750 Å2 on NHBA-C3, and ~950 Å2 on the Fab, as calculated by PISA [119]. These buried surfaces at 
the epitope-paratope interface correspond to ~11% and ~4% of the total surface area of NHBA-C3 
and 5H2, respectively. Five strands forming the C-terminal face of the β-barrel (strands β1-β4 and β8) 
(Fig. 3.18) compose the epitope of NHBA, involving 27 antigen residues that contact 18 antibody 
residues. Loops forming the 5H2 CDRs fill the grooves of the conformational epitope surface, creating 
a remarkable epitope-paratope shape complementarity that involves the entire C-terminal face of the 
β-barrel (Fig. 3.18). The recognition is dominated by the 5H2 H chain, which contacts all three CDRs 
in a surface area of ~530 Å2 (corresponding to 19 residues) of the antigen. Instead, the 5H2 L chain 
interacts with only ~210 Å2 (corresponding to 8 residues) of the surface epitope. Also, the CDR-L2 is 
almost completely excluded from the recognition. The 5H2 H chain engages in polar contacts with 
Asn320, Glu322, Lys367, Glu425, and Arg339 of NHBA, through both main and side chains atoms 
(Fig. 3.18B, Table 9). Interactions between the conformational epitope and the H chain include a salt 
bridge (between NHBA Arg339 and 5H2 Asp100) and a hydrogen bond between the side-chains of 
NHBA Glu322 and 5H2 Ser56 (Fig. 3.18B). Additionally, epitope side chains of Glu425, Asn320 and 
Lys367 are positioned within H-bonding distance from backbone atoms of 5H2 Ser31, Ser33 and 
Ala105, respectively. There are also multiple interactions between NHBA-C3 and the 5H2 L chain, 
which include a network of well-positioned hydrogen bonds distributed around the NHBA loops made 
of residues 357-364 and 382-387. On loop 357-364, 5H2 Try92 forms H-bonds between the side chain 
OH group and the backbone O of Met363, and between the Tyr92 main chain O and the side chain O 
of Thr365. In addition, the OD2 of NHBA Asp360 is hydrogen-bonded to the backbone N of 5H2 
Ser94. Finally, the side chain of NHBA Glu383 makes an H-bond with the hydroxyl group of 5H2 
Tyr32, while the NHBA Asp360 makes interactions with the backbone N of 5H2 Ser94 (Fig. 3.18B, 
Table 9).  
The distribution of the electrostatic potential on the surfaces of NHBA-C3 and 5H2 showed 
remarkable complementarity with several charged patches on the epitope interfacing opposite charged 
regions of 5H2 (Fig. 3.19B). Interestingly, a pocket can be observed at the interface between the H 
and L chains of 5H2, where Asp100 forms a negatively charged floor surrounded by a wall of 
hydrophobic residues made of Tyr35, Tyr52, and Phe102. This funnel-shaped pocket accommodates 
NHBA Arg339 which is positioned centrally on the NHBA epitope and forms a salt bridge between its 
side chains NH1 and the O of 5H2 Asp100. At the same time, the aromatic groups of Tyr35, Tyr52, 
and Phe102 surround and seem to trap the long aliphatic arginine side chain with favorable 
hydrophobic interactions. Similar complementarities could be observed for the NHBA negatively 
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charged patches composed by Glu425-Asn320 (Fig. 3.19B), which interact with the predominantly 
positive loops CDR-H1 (Ser31-Gly32-Ser33) or NHBA Asp356-Asp60 facing a positive patch made of 
5H2 Lys60 (chain H) and Gly93-Ser94 of the CDR-L3. 
 
Molecular bases of Fab 5H2 binding 
The high resolution of the X-ray complex structure enabled us to identify three main areas of 
NHBA-C3 that are contacted by 5H2: 1) the region interacting with the Fab light chain that engages 
polar contacts with NHBA residues Thr365 and Asp360, 2) the region interacting with Fab heavy chain 
comprising residues Glu322 and Glu425 3) the core region of the epitope made of residues Arg339 
and K367. Hence, to investigate the precise relative importance of NHBA-C3 residues that interact 
with Fab 5H2, seven NHBA-C3 mutants were generated in the attempt of disrupt these interactions: 
Arg339Ala, Arg339Gly, Lys367Ala, Arg339Ala-Lys367Ala, Arg339Gly-Lys367Ala, Thr365Ala-
Asp360Ala and Glu322Ala-Glu425Ala (Fig. 3.20). The constructs including the mutation of the 
 
Figure 3.19. Electrostatic potential of the complex interface. (A) Side view of the Fab 5H2:NHBA-C3 
complex, with the epitope-paratope surface colored according to the electrostatic potential distribution. A yellow 
dotted line divides the 5H2 and NHBA surfaces. (B) Open book view of the interfacing epitope-paratope surfaces. 
Circles with the same layout represent complementary regions. 
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conserved Arg339 to Ala or Gly were designed to assess the relevance of the long Arg side chain that 
protrudes with its polar head to reach inside a groove into the 5H2 paratope (see Fig.3.18C). Double 
mutants of Arg339 and Lys367 were designed in order to verify if there is a cumulative effect on Fab 
binding in presence of multiple mutations. Finally, the last two mutants (Thr365Ala-Asp360Ala and 
Glu322Ala-Glu425Ala) were generated for the evaluation of the role of 5H2 light and heavy chain in 
the binding to NHBA-C3.  
 
After successful expression and purification, the thermostability of the NHBA-C3 mutants was 
assessed by DSC, which revealed how mutations localized on the most peripheral regions of the 
epitope (i.e. Lys367Ala, Thr365Ala-Asp360Ala and Glu322Ala-Glu425Ala) did not significantly affect 
the melting temperature (Tm) with respect to the wild-type (Fig. 3.21A). Instead, mutations involving 
Arg339 (Arg339Ala, Arg339Gly, Arg339Ala-Lys367Ala, Arg339Gly-Lys367Ala) resulted in a significant 
thermal destabilizations, as they induced a decrease in the Tm of up to ~7°C (Fig. 3.21A). 
Interestingly, the most dramatic effects were observed for constructs carrying the Arg339Gly mutation.  
Finally, the effect of these mutations on the 5H2 binding was studied by SPR, by first capturing Fab 
5H2 on a sensor chip, and then injecting, separately and at the same concentration, the seven NHBA-
C3 mutants. These expertiments showed that mutations to Ala of residues Glu322, Glu425, or Lys367, 
involved in direct interactions with Fab heavy chain, are not critical for 5H2 binding, while mutation of 
residues Thr365 and Asp360, which make polar contacts with the 5H2 L chain, result in a 4-fold 
 
Figure 3.20. Overview of NHBA-C3 mutated residues. The 5H2 epitope is depicted as grey surface, while the 
mutated residues are highlighted in yellow and are labelled. 
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reduction in binding (Fig. 3.21B). However, the key determinants of the NHBA-5H2 interaction seem a 
combination of bonds mediated by both Arg339 and Lys367; while mutation of Arg339 to Gly results in 
a 2-fold reduction only, mutation to Ala does completely inhibit the binding. The same can be observed 
when mutating Arg339 to either Gly or Ala in combination with the Lys to Ala mutation in position 367. 
It is likely that the 5H2 Asp100 that forms a salt bridge with Arg339 (Fig. 3.18C) contributes to more 
repulsive interactions with Ala than with Gly, being the former bulkier and slightly more hydrophobic. 
The DSC data also suggest that the decreased thermo-stabilities of the Ala and Gly mutants of 
residue Arg339 (3.3 and ~6.7 degrees less stable than wild-type, respectively) do not result in major 
structural rearrangements or unfolding of NHBA. Such observation might explain the observed 
difference in binding of these mutants (i.e. the more destabilized mutant Arg339Gly shows residual 
binding by 5H2, while the less destabilized Arg339Ala is not recognized anymore by 5H2). 
 
 
 
 
Figure 3.21. DSC and SPR studies of NHBA-C3 mutants. (A-Left) DSC profiles of NHBA-C3 mutants, and  
(Right) observed Tm values. (B) Sensorgrams profile of the SPR analysis performed using captured Fab 5H2 and 
NHBA-C3 mutants. The colors corresponding to each mutant are reported on the right. 
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Structural changes upon complex formation  
To investigate possible structural changes of Fab 5H2 upon binding to NHBA-C3, structural 
superpositions of the variable domains of the unbound and bound 5H2 structures were performed with 
SSM in Coot [107]. This revealed that Fab 5H2 undergoes local structural rearrangements upon 
binding of NHBA-C3 to better fit the interacting surfaces. Structural reorganization resulted particularly 
evident for residues Tyr35, Tyr52 and Phe102, which are located in the 5H2 H chain (Fig. 3.22A and 
B). Movement of the side chains of these residues seems to create a funnel-shaped pocket that 
accommodates NHBA Arg339 (Fig. 3.22D). While the side-chain of Phe102 is displaced by up to 10.5 
Å, minor shifts can be observed for the side chains of Tyr35 and Tyr52. Additional conformational 
changes could be observed for the 5H2 CDR-H3 loop, likely influenced also by rearrangements of the 
nearby CDR-L2 (residues Tyr49-Ser60), which lacks electron density for one of the chains (O) thus 
suggesting intrinsic flexibility (Fig. 3.22B and C).  
 
 
Figure 3.22. Binding-induced conformational changes in the 5H2 structures. (A) Rotamers of residues 
Phe102, Tyr35 and Tyr52 of the unbound Fab 5H2 chains HL (green) and chains OP (raspberry), compared to 
those of the NHBA-C3-bound Fab 5H2 chains HL (blue). (B) Top view of the superposition between unbound Fab 
5H2 chains HL, MN (orange), OP and NHBA-C3-bound Fab 5H2 chains HL (blue) and IM (dark blue). Region with 
the major differences are boxed. (C) Zoom into CDR-H3 and CDR-L2 of the unbound Fab 5H2 chains OP and 
NHBA-C3-bound Fab5H2 chains HL, where a dotted line shows the missing atoms of the CDR-L2 from the OP 
chains. (D) Surfaces of the triad Phe102-Tyr52-Tyr35 of the unbound 5H2 structures are shown on top, compared 
with the NHBA-C3-bound 5H2 chains HL (bottom).  
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Measurements of the 5H2 elbow angles in its different states were also performed in order to study 
their structural deviations upon binding to NHBA. In the case of unbound-5H2, a remarkable oscillation 
was observed among the elbow angles calculated for each of the three unbound-5H2 molecules 
present in the ASU. These angles ranged from 122.58° and 122.20° for chains HL and MN, up to 
146.10° for chains OP (Fig. 3.23). In contrast, the two ASU copies of the NHBA-C3-bound 5H2 
displayed a rather similar elbow bend of 135.57° and 136.12°, respectively. As expected, this suggests 
that the hinge region between C and V chains of the bound 5H2 have restricted degrees of freedom if 
compared to their conformations when in the unbound state. It has been previously proposed that a 
relationship between the change in elbow angle and antigen binding exists [140-142]. Moreover, 
antigen recognition can lead to conformational changes in the variable domains that is subsequently 
transmitted to the constant domains [74]. Importantly, not all known structures of Fabs have different 
elbow angles for their free and unbound states [140, 143].  
 
Taken together, our observations on the structural rearrangements of the 5H2 paratope upon 
binding of the NHBA-C3 seem to agree with the pre-existing equilibrium hypothesis in combination 
with the induced fit model as general mechanism of antibody-antigen recognition [144]. According to 
the pre-existing equilibrium hypothesis, antibodies can assume a set of multiple conformations in 
solution that are closely related to each other, with a shift towards the antigen binding preferred 
conformation as soon as they engage in complex formation. This could drive the so-called early 
 
Figure 3.23. The elbow angles of Fab 5H2. All elbow angles of the five different 5H2 heterodimer structures 
solved here (3 copies from the unbound structure, and 2 copies from the NHBA-C3-bound structure) are shown 
as measured with phenix.elbow. 
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binding mechanism that is then followed by induced-fit, considered as conformational changes of the 
binding region upon binding [145].  
In the case of our 5H2:NHBA-C3 complex, we first observed a distribution of possible states from 
the structure of unbound 5H2, which likely reflects the intrinsic molecular motion of 5H2 even within 
the constraints of the crystal packing environment. Then, it is likely that the only 5H2 conformation 
observed in the complex corresponds to the one better fitting the antigen surface, and thus indicating 
a selection of the most favorable Fab conformation. This selection consisted specifically in 
conformational changes in the region of residues Try52-Tyr36-Phe102, to perfectly accommodate 
Arg339 from NHBA-C3 (Fig.3.22).  
NHBA β-barrel conservation and 5H2 cross-reactivity 
In order to analyze the 5H2 cross-reactivity properties, a panel of short and long NHBA variants 
was chosen for sequence comparison. Sequences of the β-barrels from long (p2, p3, p5, p1, p29) and 
short (p18, p17, p10, p21) variants were aligned (Fig. 3.24) against the sequence of variant p20, from 
which the construct NHBA-C3 was obtained. 
 
 
Figure 3.24. Sequence alignment of NHBA long and short variants. The 5H2 epitope is highlighted in yellow, 
while red boxes show the non-conserved residues of the 5H2 epitope. 
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 The sequence conservation is almost absolute, with the most divergent variant being p17 that has 
a sequence identity of the 97.4% with p20. Only three variants (p18, p2 and p29) showed a few point 
mutations in the region of the mapped 5H2 epitope (Fig. 3.24). More in detail, Arg337, which is 
substituted with Lys in p18 or Gly in p29, is not involved in direct polar interactions with 5H2, thus it is 
unlikely to play a critical role once mutated. Instead, substitution of Thr365 into Lys in p29 could 
impact the interaction with 5H2, considering that the side-chain of Thr365 is engaged in hydrogen 
bonds with the 5H2 Tyr92 and that Lys has a higher steric hindrance compared to Thr. The other 
variant which is not fully conserved is p2, for which the experimental data already demonstrated that 
mutation of Asp360 into glycine does not affect the binding affinity (Table 1, see also Fab-NHBA 
interaction studies). 
Together with the results of the binding experiments, these observations support the ability of Fab 
5H2 to efficaciously recognize all NHBA variants studied here. 
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Tables 
Table 1 
Binding affinities of Fabs 12E1, 10C3 and 5H2 towards NHBA peptides 2, 3 and 20 calculated as 
described in the Material and Methods section. 
  
Fab Protein Kon (1/M*s) 
Koff 
(1/s) KD (M) 
12E1  
NHBA p3 8.4 x10+4 3.1 x10-4 5.1 x10-10 
NHBA p20 4.9 x10
+4
 3.0 x10
-4
 6.2 x10
-9
 
NHBA p2 2.1 x10+5 5.9 x10-5 2.7 x10-10 
10C3 
NHBA p3 4.34 x10
+5
 5.41x10
-4
 1.2 x10
-10
 
NHBA p20 No binding 
NHBA p2 2.3 x10
+5
 9.2 x10
-4
 5.7 x10
-9
 
NHBA_114-332 4.9 x10+5 0.149 3.5 x10-9 
5H2 
NHBA p3 4.2 x10+5 1.7 x10-4 4.0 x10-10 
NHBA p20 5.4 x10+5 2.3 x10-4 4.3 x10-10 
NHBA p2 2.9 x10+5 1.4 x10-4 4.9 x10-10 
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Table 2 
Data collection and refinement statistics of Fabs 12 E1, 10C3 and 5H2 
 
  
 
Fab 12E1 Fab 10C3 Fab 5H2 
Wavelength (Å)  0.97932 0.979788 0.97721 
Resolution range (Å) 23.4-2.7 (2.89 - 2.75) 32.1 - 1.5 (1.55 - 1.50) 47.0 - 1.8 (1.94 - 1.88) 
Space group P 21 21 2 P 21 21 21 P 21 
Unit cell (a,b,c) 
(α,β,γ) 
64.8, 82.1, 100.3  
90, 90, 90 
69.9, 79.8, 82.5  
90, 90, 90 
82.0, 105.7, 86.2  
90, 111.9, 90 
Total reflections 65074  (6325) 264157 (23995) 325510 (32667) 
Unique reflections 14236 (1360) 73405 (7068) 109353 (10952) 
Multiplicity 4.6 (4.7) 3.6 (3.4) 3.0 (3.0) 
Completeness (%) 98.6 (97.5) 99 (97) 98.8 (99.2) 
Mean I/sigma(I) 9.9 (1.6) 14.88 (1.06) 6.6 (1.3) 
Wilson B-factor (Å2)  53.12 18.09 29.80 
R-merge 0.134 (0.897) 0.05052 (1.139) 0.082 (0.831) 
R-meas 0.151 (1.009) 0.05934 (1.349) 0.100 (1.008) 
R-pim 0.068 (0.451) 0.03079 (0.7127) 0.056  (0.563) 
CC1/2 0.993 (0.609) 0.999 (0.446) 0.994 (0.474) 
Reflections used in refinement 14204  73375 109345  
Reflections used for R-free 717  3669  5540  
R-work 0.1808 (0.2197) 0.1800 (0.3057) 0.1864 (0.2870) 
R-free 0.2638 (0.3366) 0.2114 (0.3300) 0.2265 (0.3423) 
Number of non-hydrogen atoms 3436 3857 10613 
  Macromolecules 3337 3156 9805 
  Solvent 73 701 726 
Protein residues 432 420 1291 
RMS(bonds, Å) 0.014 0.010 0.007 
RMS(angles, °) 1.96 1.27 0.94 
Ramachandran favored (%) 93.4 98 98 
Ramachandran allowed (%) 5.6 1.9 2.1 
Ramachandran outliers (%) 1 0 0 
Rotamer outliers (%) 6.6 0.84 1.3 
Clashscore 5.25 1.77 7.65 
Average B-factor (Å2)  56.44 23.88 34.65 
  Macromolecules 56.49 21.24 34.08 
  Ligands 70.63 - 50.33 
  Solvent 48.34 35.80 40.62 
Statistics for the highest-resolution shell are shown in parentheses 
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Table 3  
Description of the polar contacts between H and L chains of Fab 12E1. 
 
 
 
 
  
Bond type Light chain Dist. [Å] Heavy chain 
Hydrogen 
bond 
 
 L:GLN  43 [ NE2]  3.18 H:TYR  95 [ OH] 
 L:SER  48 [ OG ]  2.95 H:GLY 106 [ O ] 
 L:ILE 122 [ N ]  3.33 H:LYS 131 [ O ] 
 L:SER 167 [ OG ]  2.73 H:PRO 169 [ O ] 
 L:GLN 165 [NE2]  3.36 H:LEU 172 [ O ] 
 L:SER 181 [OG]  3.35 H:SER 181 [ OG] 
 L:TYR  92 [OH]  3.06 H:GLN  39 [ NE2] 
 L:LEU   4 [O ]  2.81 H:ARG  44 [NH2] 
 L:SER 213 [ O ]  2.83 H:LYS 131 [ NZ ] 
 L:GLU 128 [OE2]  3.19 H:LYS 211 [ NZ ] 
Salt bridge 
 L:ASP  60 [OD1]  3.38 H:LYS 101 [ NZ ] 
 L:GLU 128 [OE2]  3.19 H:LYS 211 [ NZ ] 
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Table 4  
Analysis of 12E1 CDRs amino acid composition. The contribution of single amino acids or groups of 
amino acids clustered on the basis of their biochemical properties to the total ASA (solvent accessible 
area calculated by PSA) are expressed both in percentage and Å2. The total ASA is calculated as the 
sum of the ASA of each residues belonging to the CDRs. 
 
 
 
  
 Fab 12 E1 
type % on ASA Amino acid ASA (Å2) % on ASA 
aromatic 18,93 
Tyr  373,35  9,70 
Trp  240,42  6,25 
Phe 114,77 2,98 
 28,84 
Lys  513,73  13,35 
  positive His 
 144,41  3,75 
  Arg 
 451,67  11,74 
negative 7,72 Asp  239,15  6,21 Glu 57,85 1,50 
polar uncharged 28,97 
Ser  378,39  9,83 
Asn  290,85  7,56 
Gln  103,75  2,70 
Thr  225,57  5,86 
Pro  116,60  3,03 
Cys 0 0,00 
non polar  15,54 
Ile 
 262,38  6,82 
Gly 
 176,57  4,59 
Leu 
 88,66  2,30 
Val  36,67  0,95 
Ala 8,99 0,23 
Met  24,99 0,65 
Total 100,00 
  3848,77 100,00 
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Table 5 
List of all the solved 10C3 datasets. Column I: starting material used for the crystallization experiment; 
Column II: identification number of the dataset; Column III: crystallization conditions; Column VI: 
resolution of each dataset; Column V and VI: cell dimensions and SG; column VII: rmsd values 
obtained by SSM of each dataset to the reference one. 
 
starting 
crystallization 
material 
# 
dataset
 
Mother liquor composition
 
Resolution
 
cell dimension  
(a b c)
 
SG
 
SSM 
r.m.s.d.(Å)
 
(1) 
Crystal of 
unbound Fab 
10C3 
1 0.2 M LiSO4 , 0.1 M BIS-TRIS 5.5 pH , 25 %w/v PEG 3350 1.9Å 69.30 76.58 82.14 P 21 21 21 0.33 
2 0.1 M KSCN , 30 %w/v PEG MME 2000 1.8Å 69.67 76.78  82.29 P 21 21 21 1.01 
3 0.1 M KSCN , 30 %w/v PEG MME 2000 1.9Å 69.72 77.69  82.49 P 21 21 21 0.76 
4 0.2 M NH4 Acet ,  0.1 M BIS-TRIS 5.5 pH ,  25 %w/v PEG 3350 1.9Å 69.65 77.91 82.35 P 21 21 21 0.67 
5 0.2 M (NH4)2H Cit ,  20 %w/v PEG 3350 1.8Å 69.65 77.31 82.05 P 21 21 21 0.88 
6 37.5 %w/v M1K3350, 0.1 M MB1 6.5 pH , 10 % MAA 2.2 Å 69.61 74.24 82.41 P 21 21 21 0.97 
7 0.2 M NH4 Acet , 0.1 M Na3 Cit 5.6 pH , 30 %w/v PEG 4K 1.7 Å 69.74 78.69 82.89 P 21 21 21 0.23 
(2) 
Crystals of 
complexed 
Fab 10C3 
8 0.2 M Ammonium sulfate 0.1 M Sodium acetate pH  4.6, 25 % w/v PEG 4000 1.89 Å 69.17  76.8  82.53 P 21 21 21 0.56 
9 0.2 M Ammonium sulfate 30 % w/v PEG 4000 1.53 Å 67.93 75.54 81.87 P 21 21 21 0.44 
10 0.2 M Magnesium chloride hexahydrate 0.1 M MES pH6.0 20 % w/v PEG 6000 1.69 Å 69.33 76.81 82.28 P 21 21 21 0.76 
11 0.2 M Magnesium chloride hexahydrate 0.1 M MES pH6.0 20 % w/v PEG 6000 1.28 Å 69.49 78.11 82.86 P 21 21 21 0.36 
12 0.2 M Calcium chloride dihydrate 0.1 M MES pH6.0 20 % w/v PEG 6000 1.44 Å 76.77 82.04 68.80 P 21 21 21 0.58 
(3) 
Crystals of 
Soaked Fab 
10C3 
13 0.2 M NaCl , 0.1 M Na Phos Cit 4.2 pH , 20 %w/v PEG 8000 2.2Å 70.19 78.15 83.86 P 21 21 21 0.43 
14 0.2 M NaCl , 0.1 M Na Phos Cit 4.2 pH , 20 %w/v PEG 8000 1.5Å 69.51 78.52 82.73 P 21 21 21 0.24 
15 0.17 M (NH4)2SO4 , 15 %v/v Glycerol , 25.5 %w/v PEG 4000 1.5 Å 69.91 79.83 82.58 P 21 21 21 reference 
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Table 6 
Description of the polar contacts between H and L chains of Fab 10C3. 
 
Bond type Light chain Dist. [Å] Heavy chian 
Hydrogen bond 
H:GLN  39 [ NE2] 3.0 L:GLN 40[ OE1 ] 
H:ASN  59 [ ND2] 2.9 L:SER 97[ O ] 
H:TYR  95 [ OH ] 3.8 L:THR  44 [ O  ] 
H:LYS 145 [ NZ ] 2.7 L:THR 135 [ OG1] 
H:SER 174 [ OG ] 3.0 L:GLU 164 [ OE2] 
H:SER 174 [ N  ] 3.3 L:GLU 164 [ OE2] 
H:SER 181 [ OG ] 2.9 L:TYR 181 [ OH ] 
H:GLN  39 [ OE1] 3.1 L:GLN  40 [ NE2] 
H:GLN  43 [ O  ] 3.5 L:TYR  89 [ OH ] 
H:ASP 101 [ O  ] 3.1 L:SER  36 [ OG ] 
Salt bridge 
H:TYR  95 [ OH ] 3.7 L:GLN  40 [ NE2] 
H:LYS 211 [ NZ ] 2.9 L:GLU 127[ OE1 ] 
H:LYS 211 [ NZ ] 3.3 L:GLU 127[ OE2 ] 
H:ASP 101 [ OD1] 2.8 L:ARG 34 [ NH1 ] 
H:ASP 101 [ OD1] 3.6 L:ARG 34 [ NH1 ] 
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Table 7 
Analysis of 10C3 CDRs amino acid composition. The contribution of single amino acids or groups of 
amino acids clustered on the basis of their biochemical properties to the total ASA (solvent accessible 
area calculated by PISA [119] ) are expressed both in percentage and Å2. The total ASA is considered 
the sum of ASA of each residues belonging to the CDRs. 
 Fab 10C3 
type % on ASA Amino acid ASA (Å2) % on ASA 
aromatic 18,16 
Tyr 422,48 11,71 
Trp 218,67 6,06 
Phe 14,05 0,39 
positive 13,47 
Lys 101,79 2,82 
His 134,04 3,72 
Arg 249,96 6,93 
negative 8,14 Asp 227,42 6,30 Glu 66,07 1,83 
polar uncharged 46,53 
Ser 718,75 19,92 
Asn 547,36 15,17 
Gln 0 0,00 
Thr 381,09 10,56 
Pro 31,46 0,87 
Cys 0 0,00 
non polar 13,71 
Ile 51,88 1,44 
Gly 202,27 5,61 
Leu 51 1,41 
Val 185,44 5,14 
Ala 3,86 0,11 
Met 0 0,00 
Total 100,00 
 
3607,59 100,00 
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Table 8  
Data collection and refinement statistics for 5H2-NHBA-C3 complex 
 
5H2:NHBA-C3 
Wavelength (Å) 0.97950 
Resolution range (Å) 91.05 - 2.86 (2.93  - 2.86) 
Space group P 61 2 2 
Unit cell (a,b,c)  
(α,β,γ) 
119.45, 119.45, 364.22  
90, 90, 120 
Total reflections 710332  (50746) 
Unique reflections 36576 (3562) 
Multiplicity 19.4  (19.3) 
Completeness (%) 100 (100) 
Mean I/sigma (I) 18.4  (1.0) 
Wilson B-factor (Å2) 88.02 
R-merge 0.189 (3.765) 
R-meas 0.194 (3.866) 
R-pim 0.044 (0.875) 
CC1/2 0.999 (0.557) 
Reflections used in refinement 36559 (3559) 
Reflections used for R-free 1775 (182) 
R-work 0.1921 (0.3393) 
R-free 0.2384 (0.3750) 
Number of non-hydrogen atoms 8326 
  Macromolecules 8260 
  ligands 20 
  solvent 46 
Protein residues 1100 
RMS(bonds, Å) 0.014 
RMS(angles, °) 1.93 
Ramachandran favored (%) 96 
Ramachandran allowed (%) 3.2 
Ramachandran outliers (%) 0.55 
Rotamer outliers (%) 11 
Clashscore 5.45 
Average B-factor (Å2)  84.53 
  macromolecules 84.60 
  ligands 91.57 
  solvent 67.94 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table 9 
Polar contacts between Fab 5H2 light chain (LC), heavy chain (HC) and NHBA-C3. 
 
POLAR CONTACTS 5H2-LC:NHBA-C3
 
 
LIGHT CHAIN
 
 Dist. [Å] 
 
 NHBA-C3 
 
Hydrogen bonds     
 L:TYR  32[ OH ]  
 3.47   A:GLU 383[ OE2]  
 L:TYR  92[ OH ]  
 2.88   A:MET 363[ O ]  
 L:SER  94[ N  ]  
 2.90   A:ASP 360[ OD2]  
 L:ASN  31[ OD1]   3.64   A:LYS 367 NZ ]  
 L:TYR  92[ O ]  
 2.67   A:THR 365[ OG1]  
POLAR CONTACTS 5H2-HC:NHBA-C3
 
HEAVY CHAIN 
 
 Dist. [Å] 
 
 NHBA-C3 
 
Hydrogen bonds     
 H:SER  31[ OG ]  
 3.44   A:GLU 425[ OE2]  
 H:SER  33[ N ]  
 3.84   A:ASN 320[ OD1]  
 H:SER  56[ OG ]  
 3.07   A:GLU 322[ OE2]  
 H:ALA 105[ O ]  
 3.40   A:LYS 367[ NZ ]  
Salt bridges      
 H:ASP 100[ OD2]  
 3.20   A:ARG 339[ NH1]  
 H:ASP 100[ OD1]  
 3.97   A:ARG 339[ NH1]  
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Discussion  
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Vaccination is widely considered as one of the most effective tools to prevent infectious diseases 
and preserve human health worldwide. At the root of vaccines’ success is the mechanism by which 
vaccinations provide the vaccinee with the ability to respond to microbial infections with the prompt 
production of specific protective antibodies against a certain pathogen. Accordingly, understanding the 
characteristics of antibodies generated either upon infection or upon vaccination, as well as the exact 
role that vaccine antigens play for the immune recognition and ensuing response, represent powerful 
tools for vaccine research [21]. For many years, the rate limiting step in the analysis of the antibody 
repertoire has been the intrinsic complexities of the isolation of antibodies. Numerous technological 
advances in the last decade now enable the successful isolation and generation of monoclonal 
antibodies from B-cells, which naturally become key reagents for vaccines research, as they allow to 
discover key epitopes potentially useful in vaccine design [20]. For example, the use of monoclonal 
antibodies to reveal protective epitopes is at the base of the vaccine design strategies in programs 
such as those against diseases caused by human cytomegalovirus (CMV) [146, 147], influenza [148], 
and HIV-1 [149]. Together with the latest developments in human immunology, structural biology also 
plays a significant role in modern vaccine discovery and development programs [20] and the interplay 
between structural biology and human immunology can provide in-depth insights required to enable 
antigen design. The work described in this thesis is an example of the application or combination of 
the recent human B-cell technologies with structural biology, with a focus on the latter. 
A recent large study for the isolation of human mAbs from subjects immunized with the MenB 
vaccine Bexsero, allowed the profiling of the B-cell repertoire induced by this vaccine, and enabled the 
identification of mAbs specific for all the three vaccine antigens [90, 91]. Importantly, this study 
revealed the presence of multiple protective epitopes in each antigen and the importance of their 
simultaneous recognition by different antibodies for functional bactericidal activity. In the specific case 
of NHBA, three antibodies (10C3, 12E1, 5H2) were shown to induce bactericidal killing in serum 
bactericidal assays (SBA) when combined together [91]. Interestingly, bactericidal killing was 
observed only when one mAb against the N-terminal (i.e. 10C3 or 12E1) and one targeting the C-
terminal (i.e.5H2) were used simultaneously, while this effect could not be observed when the two 
anti-N-terminal mAbs were coupled without 5H2. This evidence guided their choice for further 
investigation performed in this work. 
One of the aims of this study was the structural determination of those regions of NHBA 
(specifically the N-terminal domain) whose structures are still unknown. To achieve this, we sought to 
use complexes with Fabs, as these are generally known to stabilize the antigen they bind to, and 
consequently to increase chances of crystallization. This is the reason why Fabs have been defined as 
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crystallization chaperones [89], with many examples in the PDB of difficult-to-crystallize proteins 
whose structures have been ultimately obtained thanks to their complexation with specific Fab 
fragments [150-152]. Disappointingly, various and numerous attempts to obtain crystals of full length 
or sub-full length NHBA fragments (that included the yet to be determined N-terminal region) 
complexed with human Fabs that were made available by the B-cell profiling study mentioned above, 
failed. This is somewhat in agreement with the predicted intrinsic disorder of the first 200 residues of 
NHBA that was already reported [64, 130]. Also, extensive bioinformatics analyses and additional 
experimental evidences collected in this study, such as a detected larger hydrodynamic radius in 
solution and unexpected elution profiles in size exclusion chromatography and SDS-PAGE, confirmed 
the hypothesis of predicted disorder. In principle, we reasoned that the choice of using Fabs that 
targeted the N-terminal disordered regions (see Fabs 10C3 and 12E1) as crystallization chaperones 
could stabilize those regions and aid the crystallization of the complexes. Also, Fab 10C3 seemed the 
most promising candidate as its putative binding site belonged to a region for which some structured 
elements (α-helices and β-strands) were predicted by our bioinformatics analyses. Moreover, thermo-
stability studies on the construct NHBA_114-332 revealed an unfolding event at ~55°C, which being 
associated to this specific region of the N-terminal domain suggests the presence of some secondary 
structure elements. It is tempting to speculate that these regions might contain transient and 
metastable conformations that could be stabilized upon binding of Fab 10C3. However, our work 
confirmed the difficulties in crystallizing a protein complex containing one or more flexible regions, 
even if coupled with a putatively stabilizing binder such as the Fab used here. In fact, none of the 
complexes between Fabs 12E1 or 10C3 and NHBA fragments resulted in crystals suitable for 
consequent structural studies.  
As a rescue strategy, in-situ proteolysis experiments were also performed on a 10C3:NHBA 
complex sample. Here, we hypothesized that the addition of protease traces in the crystallization mix 
could cause the degradation of unstable regions of the complexes, thus facilitating the crystallization 
of the remaining and stable portions. This approach is known as in-situ proteolysis, in which the 
proteolytic reaction is performed directly in the crystallization drops, and it has been previously 
demonstrated as an effective rescue strategy for crystallization of proteins recalcitrant to crystallization 
[103, 153, 154]. In these examples pertaining to other unstable or flexible proteins, the use of 
proteases did indeed help in identifying the stable domains by removing one or more regions that 
being unstructured were sensitive to proteolysis [155], and thus finally allowed their successful 
crystallization. Although several proteases, at different concentrations, and several complex:protease 
molar ratios were tested, our attempts resulted only in the crystallization of free Fab 10C3, suggesting 
dissociation of the complex despite the high affinity between the components. It is possible that the 
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proteolytic cleavage affected extensive regions of NHBA, thus causing dissociation of the complex. 
This might provide a further but indirect evidence of NHBA inherent flexibility (see protease 
susceptibility), also in agreement with one of the reported hallmarks of IDPs [129, 156].  
One important outcome of all the attempts made here to obtain the structures of NHBA-Fab 
complexes was the elucidation at high-resolution of the crystal structures of all the Fabs in their 
unbound or apo state. These now provide the first high resolution structural characterization of human 
Fabs against NHBA, from the antibody repertoire of Bexsero. Analyses of the structures of these Fabs 
allows the fine dissection of their paratope composition and features, and can now be exploited for 
applications in protein design to generate for example models of the interaction with their respective 
epitopes. For example, analyses of the CDRs of Fab 12E1 and 10C3 showed a prevalence of short 
side-chain-containing residues like Ser and Thr, alongside to Tyr, which is in agreement with previous 
general observations on the average composition of antibodies paratopes [132, 134, 136, 157]. 
Interestingly, the CDRs of both Fabs 12E1 and 10C3 also displayed a significant percentage of 
positive and negative residues as Lys, Arg, and Asp (Tables 4 and 7), positioned to form charged 
patches on the antibody surfaces which were surrounded by amino acids with hydrophilic functional 
groups. For Fab 12E1, an observed enrichment in positively-charged residues could be related to the 
fact that its putative epitope is mainly acidic (made of residues 73-AAVSEENTGN-82 [91]). Also, the 
12E1 paratope displays a marked concave topology and it is also rich in hydrophobic residues (Tyr 
and Trp), both features previously reported to distinguish antibodies that bind disordered epitopes or 
intrinsically disordered proteins [138, 158]. Also for Fab 10C3 similar patches of charged residues, 
especially positively-charged, were detected, which again could correlate with the composition of its 
putative epitope (243-KSEFEKLSDADKISNYKKDGKNDGKNDKFVGL-274 [90]). In general, an overall 
enrichment in charged residues in the paratopes of antibodies that bind intrinsically-disordered 
proteins is thought to be due to more favorable putative charge-charge interactions that in turn might 
result in more interfacial complementarity as compared instead with the distribution of charged 
residues in other 3D complexes [158].  
A second major result of this work is the first co-crystal structure of a NHBA:Fab complex, obtained 
by co-crystallizing Fab 5H2 with a C-terminal fragment of NHBA (construct C3). The high resolution 
epitope mapping provided by this co-crystal structure shows how an entire face of the NHBA β-barrel 
is recognized as a large conformational epitope by Fab 5H2. We called this side of the antigen 
“proximal” or C-terminal face of NHBA, with “distal” face the one putatively interacting or interfacing 
with the N-terminal portion of the protein, of which we do not have structural information yet. 
Importantly, the epitope is highly conserved across a panel of NHBA strains (Fig. 3.24), and analysis 
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of the structure revealed the molecular bases of how only minor sequence variations in the epitope 
composition of a few NHBA variants do not have a significant impact in the recognition of Fab 5H2. 
Detailed analysis of the 5H2:NHBA-C3 interface shows the presence of an extensive network of 
intermolecular hydrogen bonds, among which a key salt bridge between Asp100 of 5H2 and Arg339 of 
NHBA, as confirmed by stability and binding studies. Additionally, structural comparisons of the 
unbound Fab 5H2 with the NHBA-C3-bound form shows unequivocal conformational rearrangements 
at the level of side-chains making the close local environment of Arg339 of NHBA. These changes 
seem to generate a funnel-shaped pocket specifically on the 5H2 surface of the 5H2:NHBA complex, 
which is consequently filled by the long side-chain of NHBA Arg339. In addition, this pocket has a 
peculiar mixed electrostatic (floor) and hydrophobic (walls) nature, and its formation also slightly 
changes the local topology of the paratope surface (Fig. 3.18C). 
The crystal structures of unbound human Fabs described in this work represent valuable models 
for potential new computational studies of protein modeling and design. Algorithms such as Rosetta 
FlexPepDock or SnugDock [159, 160], which have been reported to perform highly accurate de-novo 
folding of peptides by calculating and selecting lowest-energy states of designed sequences, could be 
used to generate 3D models of the 10C3 and 12E1 epitope peptides starting from the low resolution 
epitope mapping information already available [90, 91]. In addition, “data-driven” docking of such 
peptide epitopes into the structurally determined Fabs paratopes could be explored. Moreover, 
computational protocols for ab-initio folding that integrate also the experimental information available 
can be used to generate models of the N-terminal NHBA, around the binding region of Fab 10C3. To 
increase the reliability of such ab-initio folded models, the docked Fab-epitopes obtained above could 
also be used to provide structural constraints for their refinement and partial validation. 
Given the importance in the identification of the exact location of B-cell epitopes, many efforts have 
been performed in order to develop computational tools that can predict epitopes on a given antigen. 
However, given the complexity of Ab-Ag interactions, the performances of these methods have been 
disappointing [161, 162]. It is believed that one of the reasons of this weakness is the lack of large 
enough standard datasets, as data for building structure-based models are still scarce although the 
number of resolved antigen-antibody structures available in the PDB is steadily increasing. One 
proven enhancement towards the robustness of these prediction methods is the use of 
complementary experimental structural data, such as Fabs and Fab-complexes structures [163]. 
Therefore, the structures of unbound and bound-Fabs obtained in this study might contribute to 
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enhancing the datasets that the scientific community can use to increase the performance of B-cell 
epitopes predictions. 
Overall, the structural studies performed in this work provide for the first time high-resolution data 
on human-derived Fabs specific for the vaccine antigen NHBA, elucidating the details of the 
recognition by the human immune system of a conserved epitope, and enabling in-depth analyses of 
the fine, atomic features of their paratopes or interfacing residues. In addition to contributing to the 
elucidation of the properties of one of the Bexsero antigens, these results contribute to the growing 
knowledge of antibody-antigen recognition mechanisms, and at the same time they provide useful 
experimental data for further development of structure-driven computational tools.  
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